4,090 results on '"Hong, D."'
Search Results
2. Cutting seton for the treatment of cryptoglandular fistula-in-ano: a systematic review and meta-analysis
- Author
-
Khamar, J., Sachdeva, A., McKechnie, T., Lee, Y., Tessier, L., Hong, D., and Eskicioglu, C.
- Published
- 2024
- Full Text
- View/download PDF
3. Risk Factors Analysis and Prediction Model Establishment for Carbapenem-Resistant Enterobacteriaceae Colonization: A Retrospective Cohort Study
- Author
-
Guo X, Wu D, Chen X, Lin J, Chen J, Wang L, Shi S, Yang H, Liu Z, and Hong D
- Subjects
carbapenem-resistant enterobacteriaceae ,intensive care unit ,colonization ,risk factors ,risk prediction model ,Infectious and parasitic diseases ,RC109-216 - Abstract
Xiaolan Guo,1 Dansen Wu,1 Xiaoping Chen,2 Jing Lin,1 Jialong Chen,1 Liming Wang,1 Songjing Shi,1 Huobao Yang,1 Ziyi Liu,3 Donghuang Hong1,4 1Department of Critical Care Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, People’s Republic of China; 2Computer Science and Mathematics, Fujian University of Technology, Fuzhou, Fujian, People’s Republic of China; 3Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 4Fujian Provincial Key Laboratory of Critical Care Medicine, Fuzhou, Fujian, People’s Republic of ChinaCorrespondence: Ziyi Liu, Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, No. 160, Pujian Road, Pudong District, Shanghai, 200127, People’s Republic of China, Email liu-ziyi@sjtu.edu.cn Donghuang Hong, Department of Critical Care Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, No. 134, Dongjie Street, Gulou District, Fuzhou, Fujian, 350001, People’s Republic of China, Email hongdh2003@fjmu.edu.cnPurpose: The objective of this study was to identify the risk factors associated with Carbapenem-resistant Enterobacteriaceae (CRE) colonization in intensive care unit (ICU) patients and to develop a predictive risk model for CRE colonization.Patients and Methods: In this study, 121 ICU patients from Fujian Provincial Hospital were enrolled between January 2021 and July 2022. Based on bacterial culture results from rectal and throat swabs, patients were categorized into two groups: CRE-colonized (n = 18) and non-CRE-colonized (n = 103). To address class imbalance, Synthetic Minority Over-sampling Technique (SMOTE) was applied. Statistical analyses including T-tests, Chi-square tests, and Mann–Whitney U-tests were employed to compare differences between the groups. Feature selection was performed using Lasso regression and Random Forest algorithms. A Logistic regression model was then developed to predict CRE colonization risk, and the results were presented in a nomogram.Results: After applying SMOTE, the dataset included 198 CRE-colonized patients and 180 non-CRE-colonized patients, ensuring balanced groups. The two groups were comparable in most clinical characteristics except for diabetes, previous emergency department admission, and abdominal infection. Eight independent risk factors for CRE colonization were identified through Random Forest, Lasso regression, and Logistic regression, including Acute Physiology and Chronic Health Evaluation (APACHE) II score > 16, length of hospital stay > 31 days, female gender, previous carbapenem antibiotic exposure, skin infection, multi-site infection, immunosuppressant exposure, and tracheal intubation. The risk prediction model for CRE colonization demonstrated high accuracy (87.83%), recall rate (89.9%), precision (85.6%), and an AUC value of 0.877. Patients were categorized into low-risk (0– 90 points), medium-risk (91– 160 points), and high-risk (161– 381 points) groups, with corresponding CRE colonization rates of 1.82%, 7.14%, and 58.33%, respectively.Conclusion: This study identified independent risk factors for CRE colonization and developed a predictive model for assessing the risk of CRE colonization.Keywords: carbapenem-resistant Enterobacteriaceae, intensive care unit, colonization, risk factors, risk prediction model
- Published
- 2024
4. The modified frailty index predicts postoperative morbidity in elective hernia repair patients: analysis of the national inpatient sample 2015–2019
- Author
-
Khamar, J., McKechnie, T., Hatamnejad, A., Lee, Y., Huo, B., Passos, E., Sne, N., Eskicioglu, C., and Hong, D.
- Published
- 2024
- Full Text
- View/download PDF
5. Cancer Immunotherapy with “Vascular-Immune” Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems
- Author
-
Jiang Z, Fang Z, Hong D, and Wang X
- Subjects
immunotherapy ,nano-delivery systems ,anti-angiogenic therapy ,“vascular-immune” crosstalk ,tumor vessels ,Medicine (General) ,R5-920 - Abstract
Zhijie Jiang, Zhujun Fang, Dongsheng Hong, Xiaojuan Wang Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, People’s Republic of ChinaCorrespondence: Xiaojuan Wang, Email xiaojuanwang1992@zju.edu.cnAbstract: Tumor vessels characterized by abnormal functions and structures hinder the infiltration and immune antigen presentation of immune cells by inducing the formation of an immunosuppressive microenvironment (“cold” environment). Vascular-targeted therapy has been proven to enhance immune stimulation and the effectiveness of immunotherapy by modulating the “cold” microenvironment, such as hypoxia and an acidic microenvironment. Notably, a therapeutic strategy based on “vascular-immune” crosstalk can achieve dual regulation of tumor vessels and the immune system by reprogramming the tumor microenvironment (TME), thus forming a positive feedback loop between tumor vessels and the immune microenvironment. From this perspective, we discuss the factors of tumor angiogenesis and “cold” TME formation. Building on this foundation, some vascular-targeted therapeutic drugs will be elaborated upon in detail to achieve dual regulation of tumor vessels and immunity. More importantly, we focus on cutting-edge nanotechnology in view of “vascular-immune” crosstalk and discuss the rational fabrication of tailor-made nanosystems for efficiently enhancing immunotherapy. Keywords: immunotherapy, nano-delivery systems, anti-angiogenic therapy, “vascular-immune” crosstalk, tumor vessels
- Published
- 2024
6. Association Between Hemoglobin-Albumin-Lymphocyte-Platelet Index and Mortality in Hospitalized COVID-19 Omicron BA.2 Infected Patients
- Author
-
Wu W, Lu W, Hong D, Yu X, and Xiong L
- Subjects
biomarkers ,covid-19 ,hemoglobin-albumin-lymphocyte-platelet index ,mortality ,omicron ba.2 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Wei Wu,1– 4,* Wenbin Lu,5,* Dongmei Hong,1– 4 Xiya Yu,1– 4 Lize Xiong1– 4 1Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Shanghai, 200434, People’s Republic of China; 2Department of Anesthesiology and Perioperative Medicine, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, 200434, People’s Republic of China; 3Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, 200434, People’s Republic of China; 4Clinical Research Centre for Anesthesiology and Perioperative Medicine, Tongji University, Shanghai, 200434, People’s Republic of China; 5Faculty of Anesthesiology, Changhai Hospital, Naval Medical University/Second Military Medical University, PLA, Shanghai, 200433, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiya Yu; Lize Xiong, Tel +86-21-55603999 ; +86-21-55603002, Fax +86-21-56660851, Email yuxiyash@163.com; mzkxlz@126.com; lizexiong@tongji.edu.cnBackground: The hemoglobin-albumin-lymphocyte-platelet (HALP) index is a novel biomarker reflecting systemic inflammation and nutritional status which are important for coronavirus disease 2019 (COVID-19) mortality. However, the association between HALP and mortality in patients with COVID-19 has yet to be investigated.Methods: A cohort of COVID-19 Omicron BA.2 infected patients admitted to the Shanghai Fourth People’s Hospital, School of Medicine, Tongji University from April 12, 2022 to June 17, 2022 was retrospectively analyzed. Laboratory examinations on hospital admission, including hemoglobin, albumin, and lymphocyte and platelet, were collected. The association between baseline HALP and in-hospital poor overall survival (OS) was assessed using Kaplan–Meier curves, Cox regression models, interaction, and stratified analyses.Results: A total of 2147 patients with COVID-19 Omicron BA.2 infection were included in the final analyses, and mortality in the hospital was 2.65%. Multivariate analysis indicated that low HALP index was independently associated with in-hospital mortality of COVID-19 patients [hazard ratio (HR) = 2.08; 95% confidence interval (CI) = 1.17– 3.73]. Subgroup analysis demonstrated that low HALP index was an independent risk factor for in-hospital mortality in COVID-19 patients with age ≥ 70 (HR = 2.22, CI = 1.18– 4.15) and severe cases (HR = 2.09, CI = 1.13– 3.86).Conclusion: HALP index is independently related to in-hospital poor OS for COVID-19 Omicron BA.2 infected patients, especially for age ≥ 70 and severe cases. HALP index on hospital admission is a useful candidate biomarker for identifying high risk of mortality in COVID-19 Omicron BA.2 infected patients.Keywords: biomarkers, COVID-19, hemoglobin-albumin-lymphocyte-platelet index, mortality, Omicron BA.2
- Published
- 2024
7. Prognostic value of cardiac magnetic resonance imaging feature tracking technology in patients with light chain amyloidosis
- Author
-
Hu, M., Shen, Y., Yu, H., Song, Y., Zheng, T., Hong, D., and Gong, L.
- Published
- 2024
- Full Text
- View/download PDF
8. Differences in in-hospital outcomes and healthcare utilization for laparoscopic versus open approach for emergency inguinal hernia repair: a nationwide analysis
- Author
-
Lee, Y., Tessier, L., Jong, A., Zhao, D., Samarasinghe, Y., Doumouras, A., Saleh, F., and Hong, D.
- Published
- 2023
- Full Text
- View/download PDF
9. The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis
- Author
-
Hong D, Lv D, Wu J, Li X, Zhao Q, Lu X, and Li L
- Subjects
diagnosis-intervention packet policy ,daily drug cost ,interrupted time series analysis ,elderly hypertension ,medication structure ,Public aspects of medicine ,RA1-1270 - Abstract
Dongsheng Hong,1,2 Duo Lv,1 Jiaying Wu,1 Xin Li,1 Qingwei Zhao,1 Xiaoyang Lu,1 Lu Li2 1Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 2Department of Social Medicine of school of Public Health, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaCorrespondence: Xiaoyang Lu, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, People’s Republic of China, Email luxiaoyang@zju.edu.cn Lu Li, Department of Social Medicine of school of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou, 310058, People’s Republic of China, Email lilu@zju.edu.cnBackground: DIP is a new medical insurance payment system developed in China which was implemented in Guangzhou in January 2018, but few studies have focused on its intervention effect on the drug burden of elderly hypertensive patients.Methods: Nine medical institutions in Guangzhou, China, were selected, among which, daily full medical orders of elderly hypertensive inpatients from 2016 to 2020 were randomly collected. To assess the impact of DIP policy intervention on patient drug burden, we took the data after policy implementation in January 2018, as the intervention data, and applied a segmented regression model with interrupted time series to analyze the trend and changes in average daily drug costs per month and medication structure, stratified by age, sex, and inpatient department.Results: A total of 34,276 elderly hypertensive patients’ daily full medical orders were obtained. The immediate level change of drug costs after intervention was − 23.884 RMB/month (P = 0.652), and the trend change was statistically significant (− 15.642 RMB/month, P = 0.002). The relative cumulative effect at the end of the study was − 78.860% (95% CI: − 86.087% to − 69.076%), and the intervention effect was more significant in surgical and male patients. The analysis of drug structure changes showed that after the implementation of the DIP policy intervention, the proportion of anti-infective drugs, anti-tumor drugs, and biological products all showed a significant downward trend (P < 0.05), while nutritional drugs showed a significant upward trend (P = 0.011), but no immediate horizontal change in slope was observed.Conclusion: The typical practice in China showed that DIP policy intervention can improve the drug burden of elderly hypertensive hospitalized patients and has a stable long-term effect, and the intervention effect is not consistent across different clinical department and populations with different characteristics, and it would also cause changes in the medication structure.Keywords: diagnosis-intervention packet policy, daily drug cost, interrupted time series analysis, elderly hypertension, medication structure
- Published
- 2023
10. Optimization of the JUNO liquid scintillator composition using a Daya Bay antineutrino detector
- Author
-
Bay, Daya, collaborations, JUNO, Abusleme, A., Adam, T., Ahmad, S., Aiello, S., Akram, M., Ali, N., An, F. P., An, G. P., An, Q., Andronico, G., Anfimov, N., Antonelli, V., Antoshkina, T., Asavapibhop, B., de André, J. P. A. M., Babic, A., Balantekin, A. B., Baldini, W., Baldoncini, M., Band, H. R., Barresi, A., Baussan, E., Bellato, M., Bernieri, E., Biare, D., Birkenfeld, T., Bishai, M., Blin, S., Blum, D., Blyth, S., Bordereau, C., Brigatti, A., Brugnera, R., Budano, A., Burgbacher, P., Buscemi, M., Bussino, S., Busto, J., Butorov, I., Cabrera, A., Cai, H., Cai, X., Cai, Y. K., Cai, Z. Y., Cammi, A., Campeny, A., Cao, C. Y., Cao, G. F., Cao, J., Caruso, R., Cerna, C., Chakaberia, I., Chang, J. F., Chang, Y., Chen, H. S., Chen, P. A., Chen, P. P., Chen, S. M., Chen, S. J., Chen, X. R., Chen, Y. W., Chen, Y. X., Chen, Y., Chen, Z., Cheng, J., Cheng, Y. P., Cheng, Z. K., Chepurnov, A., Cherwinka, J. J., Chiarello, F., Chiesa, D., Chimenti, P., Chu, M. C., Chukanov, A., Chuvashova, A., Clementi, ., Clerbaux, B., Di Lorenzo, S. Conforti, Corti, D., Costa, S., Corso, F. D., Cummings, J. P., Dalager, O., De La Taille, C., Deng, F. S., Deng, J. W., Deng, Z., Deng, Z. Y., Depnering, W., Diaz, M., Ding, X. F., Ding, Y. Y., Dirgantara, B., Dmitrievsky, S., Diwan, M. V., Dohnal, T., Donchenko, G., Dong, J. M., Dornic, D., Doroshkevich, E., Dove, J., Dracos, M., Druillole, F., Du, S. X., Dusini, S., Dvorak, M., Dwyer, D. A., Enqvist, T., Enzmann, H., Fabbri, A., Fajt, L., Fan, D. H., Fan, L., Fang, C., Fang, J., Fatkina, A., Fedoseev, D., Fekete, V., Feng, L. C., Feng, Q. C., Fiorentini, G., Ford, R., Formozov, A., Fournier, A., Franke, S., Gallo, J. P., Gan, H. N., Gao, F., Garfagnini, A., Göttel, A., Genster, C., Giammarchi, M., Giaz, A., Giudice, N., Giuliani, F., Gonchar, M., Gong, G. H., Gong, H., Gorchakov, O., Gornushkin, Y., Grassi, M., Grewing, C., Gromov, M., Gromov, V., Gu, M. H., Gu, W. Q., Gu, X. F., Gu, Y., Guan, M. Y., Guardone, N., Gul, M., Guo, C., Guo, J. Y., Guo, L., Guo, W. L., Guo, X. H., Guo, Y. H., Guo, Z., Haacke, M., Hackenburg, R. W., Hackspacher, P., Hagner, C., Han, R., Han, Y., Hans, S., He, M., He, W., Heeger, K. M., Heinz, T., Heng, Y. K., Herrera, R., Higuera, A., Hong, D. J., Hor, Y. K., Hou, S. J., Hsiung, Y. B., Hu, B. Z., Hu, H., Hu, J. R., Hu, J., Hu, S. Y., Hu, T., Hu, Z. J., Huang, C. H., Huang, G. H., Huang, H. X., Huang, Q. H., Huang, W. H., Huang, X. T., Huang, Y. B., Huber, P., Hui, J. Q., Huo, L., Huo, W. J., Huss, C., Hussain, S., Insolia, A., Ioannisian, A., Ioannisyan, D., Isocrate, R., Jaffe, D. E., Jen, K. L., Ji, X. L., Ji, X. P., Ji, X. Z., Jia, H. H., Jia, J. J., Jian, S. Y., Jiang, D., Jiang, X. S., Jin, R. Y., Jing, X. P., Johnson, R. A., Jollet, C., Jones, D., Joutsenvaara, J., Jungthawan, S., Kalousis, L., Kampmann, P., Kang, L., Karagounis, M., Kazarian, N., Kettell, S. H., Khan, A., Khan, W., Khosonthongkee, K., Kinz, P., Kohn, S., Korablev, D., Kouzakov, K., Kramer, M., Krasnoperov, A., Krokhaleva, S., Krumshteyn, Z., Kruth, A., Kutovskiy, N., Kuusiniemi, P., Lachacinski, B., Lachenmaier, T., Langford, T. J., Lee, J., Lee, J. H. C., Lefevre, F., Lei, L., Lei, R., Leitner, R., Leung, J., Li, C., Li, D. M., Li, F., Li, H. T., Li, H. L., Li, J., Li, J. J., Li, J. Q., Li, K. J., Li, M. Z., Li, N., Li, Q. J., Li, R. H., Li, S. C., Li, S. F., Li, S. J., Li, T., Li, W. D., Li, W. G., Li, X. M., Li, X. N., Li, X. L., Li, X. Q., Li, Y., Li, Y. F., Li, Z. B., Li, Z. Y., Liang, H., Liang, J. J., Liebau, D., Limphirat, A., Limpijumnong, S., Lin, C. J., Lin, G. L., Lin, S. X., Lin, T., Lin, Y. H., Ling, J. J., Link, J. M., Lippi, I., Littenberg, L., Littlejohn, B. R., Liu, F., Liu, H., Liu, H. B., Liu, H. D., Liu, H. J., Liu, H. T., Liu, J. C., Liu, J. L., Liu, M., Liu, Q., Liu, R. X., Liu, S. Y., Liu, S. B., Liu, S. L., Liu, X. W., Liu, Y., Lokhov, A., Lombardi, P., Loo, K., Lorenz, S., Lu, C., Lu, H. Q., Lu, J. B., Lu, J. G., Lu, S. X., Lu, X. X., Lubsandorzhiev, B., Lubsandorzhiev, S., Ludhova, L., Luk, K. B., Luo, F. J., Luo, G., Luo, P. W., Luo, S., Luo, W. M., Lyashuk, V., Ma, Q. M., Ma, S., Ma, X. B., Ma, X. Y., Ma, Y. Q., Malyshkin, Y., Mantovani, F., Mao, Y. J., Mari, S. M., Marini, F., Marium, S., Marshall, C., Martellini, C., Martin-Chassard, G., Caicedo, D. A. Martinez, Martini, A., Martino, J., Mayilyan, D., McDonald, K. T., McKeown, R. D., Müller, A., Meng, G., Meng, Y., Meregaglia, A., Meroni, E., Meyhöfer, D., Mezzetto, M., Miller, J., Miramonti, L., Monforte, S., Montini, P., Montuschi, M., Morozov, N., Muralidharan, P., Napolitano, J., Nastasi, M., Naumov, D. V., Naumova, E., Nemchenok, I., Nikolaev, A., Ning, F. P., Ning, Z., Nunokawa, H., Oberauer, L., Ochoa-Ricoux, J. P., Olshevskiy, A., Ortica, F., Pan, H. R., Paoloni, A., Park, J., Parkalian, N., Parmeggiano, S., Patton, S., Payupol, T., Pec, V., Pedretti, D., Pei, Y. T., Pelliccia, N., Peng, A. G., Peng, H. P., Peng, J. C., Perrot, F., Petitjean, P. A., Rico, L. F. Pineres, Popov, A., Poussot, P., Pratumwan, W., Previtali, E., Pun, C. S. J., Qi, F. Z., Qi, M., Qian, S., Qian, X., Qian, X. H., Qiao, H., Qin, Z. H., Qiu, S. K., Rajput, M., Ranucci, G., Raper, N., Re, A., Rebber, H., Rebii, A., Ren, B., Ren, J., Reveco, C. M., Rezinko, T., Ricci, B., Robens, M., Roche, M., Rodphai, N., Rohwer, L., Romani, A., Rosero, R., Roskovec, B., Roth, C., Ruan, X. C., Ruan, X. D., Rujirawat, S., Rybnikov, A., Sadovsky, A., Saggese, P., Salamanna, G., Sangka, A., Sanguansak, N., Sawangwit, U., Sawatzki, J., Sawy, F., Schever, M., Schuler, J., Schwab, C., Schweizer, K., Selivanov, D., Selyunin, A., Serafini, A., Settanta, G., Settimo, M., Shahzad, M., Shi, G., Shi, J. Y., Shi, Y. J., Shutov, V., Sidorenkov, A., Simkovic, F., Sirignano, C., Siripak, J., Sisti, M., Slupecki, M., Smirnov, M., Smirnov, O., Sogo-Bezerra, T., Songwadhana, J., Soonthornthum, B., Sotnikov, A., Sramek, O., Sreethawong, W., Stahl, A., Stanco, L., Stankevich, K., Stefanik, D., Steiger, H., Steiner, H., Steinmann, J., Stender, M., Strati, V., Studenikin, A., Sun, G. X., Sun, L. T., Sun, J. L., Sun, S. F., Sun, X. L., Sun, Y. J., Sun, Y. Z., Suwonjandee, N., Szelezniak, M., Tang, J., Tang, Q., Tang, X., Tietzsch, A., Tkachev, I., Tmej, T., Treskov, K., Troni, G., Trzaska, W., Tse, W. -H., Tull, C. E., Tuve, C., van Waasen, S., Boom, J. Vanden, Vassilopoulos, N., Vedin, V., Verde, G., Vialkov, M., Viaud, B., Viren, B., Volpe, C., Vorobel, V., Votano, L., Walker, P., Wang, C., Wang, C. H., Wang, E., Wang, G. L., Wang, J., Wang, K. Y., Wang, L., Wang, M. F., Wang, M., Wang, N. Y., Wang, R. G., Wang, S. G., Wang, W., Wang, W. S., Wang, X., Wang, X. Y., Wang, Y., Wang, Y. F., Wang, Y. G., Wang, Y. M., Wang, Y. Q., Wang, Z., Wang, Z. M., Wang, Z. Y., Watcharangkool, A., Wei, H. Y., Wei, L. H., Wei, W., Wei, Y. D., Wen, L. J., Whisnant, K., White, C. G., Wiebusch, C., Wong, S. C. F., Wong, H. L. H., Wonsak, B., Worcester, E., Wu, C. H., Wu, D. R., Wu, F. L., Wu, Q., Wu, W. J., Wu, Z., Wurm, M., Wurtz, J., Wysotzki, C., Xi, Y. F., Xia, D. M., Xie, Y. G., Xie, Z. Q., Xing, Z. Z., Xu, D. L., Xu, F. R., Xu, H. K., Xu, J. L., Xu, J., Xu, M. H., Xu, T., Xu, Y., Xue, T., Yan, B. J., Yan, X. B., Yan, Y. P., Yang, A. B., Yang, C. G., Yang, H., Yang, J., Yang, L., Yang, X. Y., Yang, Y. F., Yang, Y. Z., Yao, H. F., Yasin, Z., Ye, J. X., Ye, M., Yegin, U., Yeh, M., Yermia, F., Yi, P. H., You, Z. Y., Young, B. L., Yu, B. X., Yu, C. X., Yu, C. Y., Yu, H. Z., Yu, M., Yu, X. H., Yu, Z. Y., Yuan, C. Z., Yuan, Y., Yuan, Z. X., Yuan, Z. Y., Yue, B. B., Zafar, N., Zambanini, A., Zeng, P., Zeng, S., Zeng, T. X., Zeng, Y. D., Zhan, L., Zhang, C., Zhang, F. Y., Zhang, G. Q., Zhang, H. H., Zhang, H. Q., Zhang, J., Zhang, J. B., Zhang, J. W., Zhang, P., Zhang, Q. M., Zhang, T., Zhang, X. M., Zhang, X. T., Zhang, Y., Zhang, Y. H., Zhang, Y. M., Zhang, Y. P., Zhang, Y. X., Zhang, Y. Y., Zhang, Z. J., Zhang, Z. P., Zhang, Z. Y., Zhao, F. Y., Zhao, J., Zhao, R., Zhao, S. J., Zhao, T. C., Zheng, D. Q., Zheng, H., Zheng, M. S., Zheng, Y. H., Zhong, W. R., Zhou, J., Zhou, L., Zhou, N., Zhou, S., Zhou, X., Zhu, J., Zhu, K. J., Zhuang, H. L., Zong, L., and Zou, J. H.
- Subjects
Physics - Instrumentation and Detectors ,High Energy Physics - Experiment - Abstract
To maximize the light yield of the liquid scintillator (LS) for the Jiangmen Underground Neutrino Observatory (JUNO), a 20 t LS sample was produced in a pilot plant at Daya Bay. The optical properties of the new LS in various compositions were studied by replacing the gadolinium-loaded LS in one antineutrino detector. The concentrations of the fluor, PPO, and the wavelength shifter, bis-MSB, were increased in 12 steps from 0.5 g/L and <0.01 mg/L to 4 g/L and 13 mg/L, respectively. The numbers of total detected photoelectrons suggest that, with the optically purified solvent, the bis-MSB concentration does not need to be more than 4 mg/L. To bridge the one order of magnitude in the detector size difference between Daya Bay and JUNO, the Daya Bay data were used to tune the parameters of a newly developed optical model. Then, the model and tuned parameters were used in the JUNO simulation. This enabled to determine the optimal composition for the JUNO LS: purified solvent LAB with 2.5 g/L PPO, and 1 to 4 mg/L bis-MSB., Comment: 13 pages, 8 figures
- Published
- 2020
11. Optical Spectroscopy for the Investigation of Transient Plasmas
- Author
-
Hong, D., Rabat, H., Ciobanu, S. S., Bauchire, J. M., Hermann, J., Bonitz, Michael, Series Editor, Takabe, Hideaki, Series Editor, Yoshida, Zensho, Series Editor, Shao, Tao, editor, and Zhang, Cheng, editor
- Published
- 2023
- Full Text
- View/download PDF
12. The Synergy of Gene Targeting Drug Icaritin Soft Capsule with Immunomodulator and TACE Brings New Hope for Drug Combination in Patients with Advanced Liver Cancer: A Case Report and Literature Review
- Author
-
Tang X, Zhang Y, Dong X, Jiang G, Hong D, and Liu X
- Subjects
hcc ,patient ,systematic and comprehensive treatment ,icaritin ,gene-targeted ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Xiaoxia Tang,1 Yizhuo Zhang,2 Xinyu Dong,2 Guixing Jiang,2 Defei Hong,2,* Xiaolong Liu2,* 1Operating Room, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 2General Surgery, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiaolong Liu; Defei Hong, Email hahapoint1234@sina.com; hongdefi@163.comAbstract: At present, the average five-year survival rate of liver cancer in China is only 12.1%. The reason for this association lies in the diagnosis at its middle or/and advanced stage of liver cancer for lacking special clinical symptoms in almost 70% of patients without the chance of effective surgical resection. Epidemiological studies have shown that there are only 30% of patients with an initial diagnosis of liver cancer have the opportunity to undergo radical surgery. Therefore, systematic and comprehensive treatment would play an important role in liver cancer treatment at its middle or/and advanced stage, and the related therapeutic schedule still needs further improvement and optimization. We applied a gene-targeted drug of Icaritin soft capsule in the treatment of a liver cancer patient at its advanced stage. And the level of AFP was found to decrease to 6.4ng/mL from 10.86ng/mL; meanwhile, MRI showed that the primary tumor significantly reduced in size, with shrinking of the hepatogastric space, hepatic aortic side, and renal artery side lymph nodes. After treatment with TACE and Icaritin, the patient had no discomfort and no longer experienced abdominal pain and bloating and gained three kilograms of weight. The therapeutic effect of Icaritin-targeted drugs was completely demonstrated during the later treatment follow-up. That is to say, the multiple anti-tumor characteristics of Icaritin with good safety were fully displayed in this case, and it can be used in combination with other drugs to treat hepatocellular carcinoma in the clinical setting. The results show that Icaritin can put some effects on the combined treatment of patients with liver cancer.Keywords: HCC, patient, systematic and comprehensive treatment, Icaritin, gene-targeted
- Published
- 2023
13. Efficacy and Mechanism of Qianshan Huoxue Gao in Acute Coronary Syndrome via Regulation of Intestinal Flora and Metabolites
- Author
-
Zhao N, Ma Y, Liang X, Zhang Y, Hong D, Wang Y, and Bai D
- Subjects
traditional chinese medicine ,acute coronary syndrome ,16s rrna ,ethanolamine ,topical paste ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Ning Zhao,1,2 Yan Ma,3 Xiaoxue Liang,2 Yu Zhang,4 Dacheng Hong,5 Ying Wang,2 Dong Bai2 1Department of Pharmacy, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China; 2Formula-Syndrome Research Center, Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China; 3Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria; 4Beijing Xiuzheng Pharmaceutical Company, Beijing, People’s Republic of China; 5Department of Pharmaceutical Sciences, University of Vienna, Vienna, AustriaCorrespondence: Dong Bai, Tel +86 13552343081, Fax +8610 64089002, Email baidong2000@126.comPurpose: To study the efficacy of Qianshan Huoxue Gao (QS) in treating acute coronary syndrome (ACS) and to explore the mechanism of action from the perspective of intestinal flora regulation.Methods: Male Sprague–Dawley rats were divided into control, model, QS, and atorvastatin groups; except for the control group, rats underwent ligation of the left anterior descending branch of the coronary artery. Following treatment for 28 days, cardiac function was evaluated using an echocardiographic assay; ELISAs for serum creatine kinase isoenzyme (CK-MB), cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-2 (IL-2), IL-6, and tumor necrosis factor-α (TNF-α); assessment of cardiac enzymes and inflammatory response; hematoxylin and eosin (HE) staining for histopathological changes in the heart, skin, and viscera; 16S rRNA gene sequencing for intestinal flora diversity and structural differences analysis; and we further investigated intestinal contents using metabolomics.Results: Compared with controls, CK-MB and cTnI were increased (P< 0.01); ejection factor and fractional shortening were decreased (P< 0.01); left ventricular internal end-diastolic dimension and left ventricular internal end-systolic dimension were increased (P< 0.01); and IL-2, IL-6, TNF-α, and hs-CRP were increased in the model group. Myocardial damage and inflammation were also observed by HE staining. QS improved these indexes, similar to the atorvastatin group; therefore, QS could effectively treat ACS. QS modulates the structure and abundance of the intestinal flora in ACS model rats, among which Bacteroides, Lactobacillus, and Rikenellaceae_RC9_gut_group are associated with cardiovascular disease. Metabolomics revealed that the intestinal metabolite content changed in ACS, with ethanolamine (EA) being the most relevant metabolite for ACS treatment by QS. EA was significantly positively correlated with Eubacterium xylanophilum group, Ruminococcus, unclassified f__Oscillospiraceae, Intestinimonas, Eubacterium siraeum group, Lachnospiraceae NK4A136 group, and norank f__Desulfovibrionaceae.Conclusion: QS can effectively treat ACS and can restore regulation of the intestinal flora. EA may be the primary metabolite of QS, exerting a therapeutic effect in ACS.Keywords: traditional Chinese medicine, acute coronary syndrome, 16S rRNA, ethanolamine, topical paste
- Published
- 2023
14. Selective spatial atomic layer deposition of Cu, Cu2O, and CuO thin films in the open air: reality or fiction?
- Author
-
Sekkat, A., Weber, M., López-Sánchez, J., Rabat, H., Hong, D., Rubio-Zuazo, J., Bellet, D., Chichignoud, G., Kaminski-Cachopo, A., and Muñoz-Rojas, D.
- Published
- 2023
- Full Text
- View/download PDF
15. Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
- Author
-
Huang Y, Zhai Y, Wu M, Chang C, Luo J, Hong D, Zhao Q, Dai Y, and Liu J
- Subjects
prostate cancer cell ,docetaxel ,drug resistance ,mtorc2 ,reverse ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Yujie Huang,1 You Zhai,1 Meijia Wu,1 Chengdong Chang,2 Jindan Luo,3 Dongsheng Hong,1 Qingwei Zhao,1 Yao Dai,4 Jian Liu1 1Research Center for Clinical Pharmacy, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 2Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 3Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 4Department of Radiation Oncology, College of Medicine, University of Florida, Gainesville, FL, USACorrespondence: Jian Liu, Research Center for Clinical Pharmacy, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China, Tel +86-571-87236560, Fax +86-571-87236531, Email lindaliu87@zju.edu.cn Yao Dai, Department of Radiation Oncology, College of Medicine, University of Florida, Gainesville, FL, USA, Tel +1-352-273-8237, Fax +1-352-273-8252, Email yaodai1111@hotmail.comPurpose: Mammalian Target of rapamycin (mTOR) plays a central role in regulating cell growth, proliferation, and cell cycle. The key component of mTORC2 is highly expressed in docetaxel-resistant prostate cells. However, the underlying molecular effects on prostate cells remain unclear.Methods: A docetaxel-resistant human prostate cell line (PC-3/DTX) was constructed to investigate the role of mTORC2 in docetaxel resistance. The lentivirus was transfected into cells to knock down the expression of Rictor, and cell viability was measured by Cell Counting Kit 8 (CCK-8). Flow cytometry was used to analyze the cell cycle, and the changes in related signal cascades were assessed by immunohistochemistry (IHC) staining and Western blot.Results: Docetaxel showed the lowest IC50 (50% inhibitory concentration) in PC-3/DTX cells with sh-RNA. Decreased Rictor expression resulted in a larger proportion of arrested cells in the G0/G1 phase in PC-3/DTX cells. The IC50 values of the AZD8055 group were lower than in the Rapamycin group when treated with docetaxel again. Furthermore, a larger proportion of PC-3/DTX cells were arrested in the G0/G1 phase in the AZD8055 group compared to the Rapamycin group. The IHC results of the prostate cancer tissues from a CRPC patient revealed the over expression of Rictor only, while Raptor expression was unaffected.Conclusion: We investigated the role of mTORC2 signaling on the acquired docetaxel -resistant PC-3 cells to identify potential methods for clinical treatment. MTORC2 expression is essential for docetaxel drug resistance of PC-3 cells. The mTORC1/2 inhibitor AZD8055 caused more significant disruption of mTORC2 kinase activity than the mTORC1 inhibitor Rapamycin, which lead to decreased docetaxel-mediated resistance. Therefore, reversing docetaxel resistance, may become a therapeutic option in the treatment of mCRPC patients.Keywords: prostate cancer cell, docetaxel, drug resistance, mTORC2, reverse
- Published
- 2022
16. INFLUENCE OF DIGITAL ELEVATION MODEL RESOLUTION ON MAPPING TERRITORY SUSCEPTIBILITY TO LANDSLIDE DEVELOPMENT
- Author
-
Van B. Duong, Igor K. Fomenko, Duc T. Ta, Trung K. Nguyen, Oleg V. Zerkal, Denis N. Gorobtsov, and Hong D. Vu
- Subjects
Landslide susceptibility of the territory ,digital elevation model resolution ,certainty factor method ,fractal method ,GIS ,area under the receiver operating characteristic curve ,Engineering geology. Rock mechanics. Soil mechanics. Underground construction ,TA703-712 - Abstract
Link for citation: Van B. Duong, Fomenko I.K., Duc T. Ta, Trung K. Nguyen, Zerkal O.V., Gorobtsov D.N., Hong D. Vu. Influence of digital elevation model resolution on mapping territory susceptibility to landslide development. Bulletin of the Tomsk Polytechnic University. Geo Аssets Engineering, 2023, vol. 334, no. 8, рр. 164-181. In Rus. The relevance. Landslides are one of the most hazardous natural disasters in the world, causing significant economic damage and human deaths. For 20 years (1995–2014), 3876 landslides killed 163658 people and injured 11689 people, as reported by the U. Haque study (2019), based on the data from 128 countries. Excluding events triggered by earthquakes, the total number of fatal landslides from 2004 to 2016 was 4862, and most landslides (75 %) occurred in Asia. In Vietnam, particularly in the northern mountainous regions, landslides frequently caused considerable losses of life and property. The systematic evaluation of landslide hazards is a crucial component of Vietnam's disaster prevention strategy. The main aim of this study is to assess the landslide susceptibility of the Batxat district, Laocai province (Vietnam), using four digital elevation model resolutions (10, 30, 40, and 60 m) and nine landslide causative factors: slope aspect, elevation, slope, distance to roads, distance to faults, distance to drainage, average monthly precipitation, land use, and weathering crust. Object of the study is the landslide susceptibility in Batxat district, Laocai province, Vietnam. Methods: Certainty Factor method, fractal method. Results. The performed analyses indicated a statistically significant relationship between the distribution of landslides and the landslide causative factors in the study area. As a result, the territory was divided into five zones according to its susceptibility to the landslide process: very low, low, moderate, high, and very high. The very low landslide susceptibility zone is less than 10 % of the study area, while the very high susceptibility zone varies from 14,95 to 18,32 %, depending on the digital elevation model spatial resolution. Analysis of the Receiver Operating Characteristics curve revealed that all models, independent of digital elevation model resolution, have good prediction efficiency, with the area under the receiver operating characteristic curve over 70 %. In addition, the Receiver operating characteristic and fractal analysis results indicated that the model with a digital elevation model spatial resolution of 60 m has the highest accuracy. This significant conclusion may be explained by the fact that the accuracy of the landslide susceptibility assessment result is dependent not only on the digital elevation model resolution but also on the ratio of the digital elevation model resolution and the average area of landslides in the study area. This conclusion proves that it is necessary to depict landslide locations and their detailed morphological characteristics on the landslide inventory maps.
- Published
- 2023
- Full Text
- View/download PDF
17. Familial Episodic Pain Syndromes
- Author
-
Shen Y, Zheng Y, and Hong D
- Subjects
familial episodic pain syndromes ,voltage-gated sodium channel ,transient receptor potential a1 ,dorsal root ganglia ,nociceptive pain ,Medicine (General) ,R5-920 - Abstract
Yu Shen,1 Yilei Zheng,1 Daojun Hong1,2 1Department of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, People’s Republic of China; 2Department of Medical Genetics, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, People’s Republic of ChinaCorrespondence: Daojun Hong, Department of Neurology, The First Affiliated Hospital of Nanchang University, 17# Yongwaizheng St, Nanchang, 330006, People’s Republic of China, Tel/Fax +86-791-8869-2511, Email hongdaojun@hotmail.comAbstract: Over the past decades, advances in genetic sequencing have opened a new world of discovery of causative genes associated with numerous pain-related syndromes. Familial episodic pain syndromes (FEPS) are one of the distinctive syndromes characterized by early-childhood onset of severe episodic pain mainly affecting the distal extremities and tend to attenuate or diminish with age. According to the phenotypic and genetic properties, FEPS at least includes four subtypes of FEPS1, FEPS2, FEPS3, and FEPS4, which are caused by mutations in the TRPA1, SCN10A, SCN11A, and SCN9A genes, respectively. Functional studies have revealed that all missense mutations in these genes are closely associated with the gain-of-function of cation channels. Because some FEPS patients may show a relative treatability and favorable prognosis, it is worth paying attention to the diagnosis and management of FEPS as early as possible. In this review, we state the common clinical manifestations, pathogenic mechanisms, and potential therapies of the disease, and provide preliminary opinions about future research for FEPS.Keywords: familial episodic pain syndromes, voltage-gated sodium channel, transient receptor potential A1, dorsal root ganglia, nociceptive pain
- Published
- 2022
18. High-fidelity dendritic sodium spike generation in human layer 2/3 neocortical pyramidal neurons
- Author
-
Gooch, Helen M., Bluett, Tobias, Perumal, Madhusoothanan B., Vo, Hong D., Fletcher, Lee N., Papacostas, Jason, Jeffree, Rosalind L., Wood, Martin, Colditz, Michael J., McMillen, Jason, Tsahtsarlis, Tony, Amato, Damian, Campbell, Robert, Gillinder, Lisa, and Williams, Stephen R.
- Published
- 2022
- Full Text
- View/download PDF
19. APPLICATION OF GIS-BASED BIVARIATE STATISTICAL METHODS FOR LANDSLIDE POTENTIAL ASSESSMENT IN SAPA, VIETNAM
- Author
-
Duong Van B., Igor K. Fomenko, Trung K. Nguyen, Thi Hong L. Vi, Oleg V. Zerkal, and Hong D. Vu
- Subjects
landslide susceptibility ,landslide potential ,frequency ratio ,landslide susceptibility analysis ,statistical index ,gis ,sapa ,vietnam ,Engineering geology. Rock mechanics. Soil mechanics. Underground construction ,TA703-712 - Abstract
The relevance. Predicting and minimizing the impact of natural disasters are critical tasks for governments worldwide, including Vietnam. Landslides are one of the most frequent types of natural disasters in Vietnam, especially in the northern mountainous provinces, resulting in significant loss of life and property. In this study, the GIS-based bivariate statistical methods were applied for assessing landslide potential in Sapa district, Laocai province, Vietnam. For assessing landslide susceptibility, nine landslide-related factors were selected, including elevation, distance to roads, slope, distance to faults, average monthly precipitation, relative relief, land use, crust weathering, and distance to drainage. The main aim of this study is to prepare landslide potential maps for the study area. In addition, the study also demonstrated the effectiveness of bivariate statistical methods for landslide susceptibility assessment. Object of the study is the landslide susceptibility in Sapa district, Laocai province, Vietnam. Methods: GIS-based bivariate statistical methods including frequency ratio, landslide susceptibility analysis, and statistical index. Results. Landslide potential maps were prepared using GIS-based bivariate statistical methods. The study area is divided into five landslide potential zones: very low, low, moderate, high, and very high. The area under the curve of the receiver operating characteristic (AUCROC) was used to evaluate the performance of these models. The success rates of the models for the training data are 74,60 % frequency ratio, 70,82 % landslide susceptibility analysis and 76,36 % statistical index. The prediction rates of the models for the testing data are 77,01 % frequency ratio, 74,36 % landslide susceptibility analysis and 78,11 % statistical index. The performance evaluation of the models revealed that all three techniques are efficient in assessing landslide potential in the study area. Study results are critical for land use planning and economic development, as well as minimizing landslide-related damage.
- Published
- 2022
- Full Text
- View/download PDF
20. SEMA3D Plays a Critical Role in Peptic Ulcer Disease-Related Carcinogenesis Induced by H. pylori Infection
- Author
-
Wang Z, Wei Y, An L, Wang K, Hong D, Shi Y, Zang A, Su S, and Li W
- Subjects
sema3d ,peptic ulcer disease ,gastric cancer ,h. pylori ,immunological micro-environment ,Medicine (General) ,R5-920 - Abstract
Zhiyu Wang, Yaning Wei, lin An, Kunjie Wang, Dan Hong, Yan Shi, Aimin Zang, Shenyong Su, Wenwen Li Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei Province, People’s Republic of ChinaCorrespondence: Wenwen LiDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, Hebei Province, People’s Republic of China, Email ww13663129901@yeah.netBackground: Immune cell infiltration plays a critical role in regulating peptic ulcer disease (PUD) and gastrointestinal cancer (GC). However, regulators of the cell signaling hubs remain unclear.Aim: This study characterizes genes that are differentially expressed in PUD and GC tissue samples. Bioinformatics is used to define the immune-associated hub genes associated with the malignant transfer process of PUD to GC.Methods: Total expression data from PUD and early-stage GC tissue samples were obtained from GEO and TCGA. Differentially expressed genes were assessed and immunological enrichment analysis was performed. Protein–protein interaction (PPI) and Cytoscape analysis were used together to identify the hub genes. CIBERSORT and COX analysis were used to analyze the differentially infiltrated immune cell landscapes and determine HR scores of the hub genes.Results: Expression data identified 437 DEGs as common to both GC and PUD tissue. Of these, 49 immune-related DEGs were grouped by function, and seven hub genes were identified by PPI analysis. The NRP2 and SEMA3D genes were then selected for survival analysis. SEMA3D had a higher hazard ratio than NRP2 and was defined as the hub for PUD carcinogenesis.Conclusion: SEMA3D was characterized as the hub gene for PUD carcinogenesis.Keywords: SEMA3D, peptic ulcer disease, gastric cancer, H. pylori, immunological micro-environment
- Published
- 2022
21. A Case of Resistant Status Asthmaticus: Resistant to Steroids and Responsive to IV Epinephrine
- Author
-
Saeed, S, primary, Hong, D, additional, Salam, E, additional, Adams, W, additional, and Harris, M, additional
- Published
- 2024
- Full Text
- View/download PDF
22. Ginsenoside Rg1 Inhibits Microglia Pyroptosis Induced by Lipopolysaccharide Through Regulating STAT3 Signaling [Retraction]
- Author
-
Yao Y, Li C, Qian F, Zhao Y, Shi X, Hong D, Ai Q, and Zhong L
- Subjects
neuroinflammation ,aim2 ,microglia ,pyroptosis ,rg1 ,Pathology ,RB1-214 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Yao Y, Li C, Qian F, et al. J Inflamm Res. 2021;14:6619–6632. The Editor and Publisher of the Journal of Inflammation Research are retracting the published article. The authors requested to correct errors with images from Figure 3, however it was found that some of the images had been duplicated with those from Yao YY, Li R, Guo YJ, et al. Gastrodin Attenuates Lipopolysaccharide-Induced Inflammatory Response and Migration via the Notch-1 Signaling Pathway in Activated Microglia. Neuromol Med. 2022;24:139–154. https://doi.org/10.1007/s12017-021-08671-1. Specifically, The images for Figure 3C, Control; p-STAT3; Lectin; Merge and LPS+Rg1(60µM); p-STAT3; Lectin; Merge have been duplicated with the images for Figure 3C, Control; NICD, Lectin; Merge and LPS; NICD, Lectin, Merge, respectively, from Yao YY et al (2022). The authors cooperated with our queries and explained the errors were made during the assembly of the figures and discovered following an internal academic review. The authors also provided the journal with original data from their study. However, the errors did raise concerns over the reliability and validity of the findings and the Editor and Publisher made the decision to retract the article and the authors do not agree with this decision. We have been informed in our decision-making by our editorial policies and the COPE guidelines. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
- Published
- 2023
23. Ginsenoside Rg1 Inhibits Microglia Pyroptosis Induced by Lipopolysaccharide Through Regulating STAT3 Signaling
- Author
-
Yao Y, Li C, Qian F, Zhao Y, Shi X, Hong D, Ai Q, and Zhong L
- Subjects
neuroinflammation ,aim2 ,microglia ,pyroptosis ,rg1 ,Pathology ,RB1-214 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Yueyi Yao,1 Changyan Li,1 Fusheng Qian,1 Yu Zhao,1 Xiaoyi Shi,1 Dan Hong,1 Qinglong Ai,2 Lianmei Zhong2 1Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, 650500, People’s Republic of China; 2Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, People’s Republic of ChinaCorrespondence: Lianmei Zhong; Qinglong AiDepartment of Neurology, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, 650032, Yunnan Province, People’s Republic of ChinaTel/Fax +86-0871-65336015Email 13888967787@163.com; aiqinglong63@163.comPurpose: Neuroinflammation runs through the whole process of nervous system diseases and brain injury. Inflammasomes are thought to be especially relevant to immune homeostasis, and their dysregulation contributes to pyroptosis. The natural compound Ginsenoside Rg1 has been shown to possess anti-inflammatory effects; however, its underlying mechanisms are not entirely clear. Therefore, this study was undertaken to investigate the role and mechanisms of Rg1 in regulating the production of inflammasomes and pyroptosis of microglia in vivo and in vitro.Methods: BV-2 microglial cells were pretreated with Rg1, stattic and interleukin-6 (IL-6), and then stimulated with lipopolysaccharide (LPS) (2μg/mL). Hoechst staining and Annexin V-FITC/PI assay were then carried out. The expression levels of cleaved-caspase-1, pro-caspase-1, interleukin-1β (IL-1β), mature-IL-1β, gasdermin D (GSDMD), activated NH(2)-terminal fragment of GSDMD (GSDMD-N), NOD-, LRR- and pyrin domain-containing 3 (NLRP3), apoptosis-associated speck-like protein containing a CARD (ASC), absent in melanoma 2 (AIM2), signal transducer and activator of transcription 3 (STAT3) and phosphorylated STAT3 in BV-2 were detected by Western blotting. Additionally, immunofluorescence staining was used to determine the expression of NLRP3 and p-STAT3 in postnatal rat brain and BV-2 microglia subjected to LPS stimulation and Rg1 pretreatment. The targets of transcription factor STAT3 were predicted by hTFtarget and chromatin immunoprecipitation (ChIP) was used to confirm the interaction between STAT3 and AIM2.Results: We showed here that Rg1 effectively inhibited the expression of inflammasomes and microglia pyroptosis induced by LPS. The targets predicted data of Rg1 from Swiss target prediction database showed STAT3 had the highest thresholds of probability score. Rg1 can regulate the phosphorylation of STAT3, which binds to the promoter region of inflammasome AIM2.Conclusion: It is suggested that STAT3 signaling can initiate the transcription activity of AIM2. Rg1 regulates microglia pyroptosis in neuroinflammation induced by LPS through targeting STAT3 signaling.Keywords: neuroinflammation, AIM2, microglia, pyroptosis, Rg1
- Published
- 2021
24. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer
- Author
-
Coleman, N., Hong, L., Zhang, J., Heymach, J., Hong, D., and Le, X.
- Published
- 2021
- Full Text
- View/download PDF
25. The effect of bariatric surgery on breast cancer incidence and characteristics: A meta-analysis and systematic review
- Author
-
Lovrics, O., Butt, J., Lee, Y., Lovrics, P., Boudreau, V., Anvari, M., Hong, D., and Doumouras, A.G.
- Published
- 2021
- Full Text
- View/download PDF
26. A review on non-thermal plasma treatment of water contaminated with antibiotics
- Author
-
Magureanu, M., Bilea, F., Bradu, C., and Hong, D.
- Published
- 2021
- Full Text
- View/download PDF
27. 1254 Resolution of persistent nocturnal hypoxia in a patient with treated obstructive sleep apnea after closure of a patent foramen ovale
- Author
-
Hong, D, Ryden, A, Currier, J, Tobis, J, and Zeidler, M
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Heart Disease ,Lung ,Cardiovascular ,Clinical Research ,Sleep Research ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Neurology & Neurosurgery ,Biological sciences ,Biomedical and clinical sciences ,Psychology - Published
- 2017
28. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
- Author
-
Krebs, M.G., Blay, J.-Y., Le Tourneau, C., Hong, D., Veronese, L., Antoniou, M., and Bennett, I.
- Published
- 2021
- Full Text
- View/download PDF
29. JUNO Conceptual Design Report
- Author
-
Adam, T., An, F., An, G., An, Q., Anfimov, N., Antonelli, V., Baccolo, G., Baldoncini, M., Baussan, E., Bellato, M., Bezrukov, L., Bick, D., Blyth, S., Boarin, S., Brigatti, A., Brugière, T., Brugnera, R., Avanzini, M. Buizza, Busto, J., Cabrera, A., Cai, H., Cai, X., Cammi, A., Cao, D., Cao, G., Cao, J., Chang, J., Chang, Y., Chen, M., Chen, P., Chen, Q., Chen, S., Chen, X., Chen, Y., Cheng, Y., Chiesa, D., Chukanov, A., Clemenza, M., Clerbaux, B., D'Angelo, D., de Kerret, H., Deng, Z., Ding, X., Ding, Y., Djurcic, Z., Dmitrievsky, S., Dolgareva, M., Dornic, D., Doroshkevich, E., Dracos, M., Drapier, O., Dusini, S., Díaz, M. A., Enqvist, T., Fan, D., Fang, C., Fang, J., Fang, X., Favart, L., Fedoseev, D., Fiorentini, G., Ford, R., Formozov, A., Gaigher, R., Gan, H., Garfagnini, A., Gaudiot, G., Genster, C., Giammarchi, M., Giuliani, F., Gonchar, M., Gong, G., Gong, H., Gonin, M., Gornushkin, Y., Grassi, M., Grewing, C., Gromov, V., Gu, M., Guan, M., Guarino, V., Guo, W., Guo, X., Guo, Y., Göger-Neff, M., Hackspacher, P., Hagner, C., Han, R., Han, Z., Hao, J., He, M., Hellgartner, D., Heng, Y., Hong, D., Hou, S., Hsiung, Y., Hu, B., Hu, J., Hu, S., Hu, T., Hu, W., Huang, H., Huang, X., Huo, L., Huo, W., Ioannisian, A., Ioannisyan, D., Jeitler, M., Jen, K., Jetter, S., Ji, X., Jian, S., Jiang, D., Jiang, X., Jollet, C., Kaiser, M., Kan, B., Kang, L., Karagounis, M., Kazarian, N., Kettell, S., Korablev, D., Krasnoperov, A., Krokhaleva, S., Krumshteyn, Z., Kruth, A., Kuusiniemi, P., Lachenmaier, T., Lei, L., Lei, R., Lei, X., Leitner, R., Lenz, F., Li, C., Li, F., Li, J., Li, N., Li, S., Li, T., Li, W., Li, X., Li, Y., Li, Z., Liang, H., Liang, J., Licciardi, M., Lin, G., Lin, S., Lin, T., Lin, Y., Lippi, I., Liu, G., Liu, H., Liu, J., Liu, Q., Liu, S., Liu, Y., Lombardi, P., Long, Y., Lorenz, S., Lu, C., Lu, F., Lu, H., Lu, J., Lubsandorzhiev, B., Lubsandorzhiev, S., Ludhova, L., Luo, F., Luo, S., Lv, Z., Lyashuk, V., Ma, Q., Ma, S., Ma, X., Malyshkin, Y., Mantovani, F., Mao, Y., Mari, S., Mayilyan, D., McDonough, W., Meng, G., Meregaglia, A., Meroni, E., Mezzetto, M., Min, J., Miramonti, L., Montuschi, M., Morozov, N., Mueller, T., Muralidharan, P., Nastasi, M., Naumov, D., Naumova, E., Nemchenok, I., Ning, Z., Nunokawa, H., Oberauer, L., Ochoa-Ricoux, J. P., Olshevskiy, A., Ortica, F., Pan, H., Paoloni, A., Parkalian, N., Parmeggiano, S., Pec, V., Pelliccia, N., Peng, H., Poussot, P., Pozzi, S., Previtali, E., Prummer, S., Qi, F., Qi, M., Qian, S., Qian, X., Qiao, H., Qin, Z., Ranucci, G., Re, A., Ren, B., Ren, J., Rezinko, T., Ricci, B., Robens, M., Romani, A., Roskovec, B., Ruan, X., Rybnikov, A., Sadovsky, A., Saggese, P., Salamanna, G., Sawatzki, J., Schuler, J., Selyunin, A., Shi, G., Shi, J., Shi, Y., Sinev, V., Sirignano, C., Sisti, M., Smirnov, O., Soiron, M., Stahl, A., Stanco, L., Steinmann, J., Strati, V., Sun, G., Sun, X., Sun, Y., Taichenachev, D., Tang, J., Tietzsch, A., Tkachev, I., Trzaska, W. H., Tung, Y., van Waasen, S., Volpe, C., Vorobel, V., Votano, L., Wang, C., Wang, G., Wang, H., Wang, M., Wang, R., Wang, S., Wang, W., Wang, Y., Wang, Z., Wei, W., Wei, Y., Weifels, M., Wen, L., Wen, Y., Wiebusch, C., Wipperfurth, S., Wong, S. C., Wonsak, B., Wu, C., Wu, Q., Wu, Z., Wurm, M., Wurtz, J., Xi, Y., Xia, D., Xia, J., Xiao, M., Xie, Y., Xu, J., Xu, L., Xu, Y., Yan, B., Yan, X., Yang, C., Yang, H., Yang, L., Yang, M., Yang, Y., Yanovich, E., Yao, Y., Ye, M., Ye, X., Yegin, U., Yermia, F., You, Z., Yu, B., Yu, C., Yu, G., Yu, Z., Yuan, Y., Yuan, Z., Zanetti, M., Zeng, P., Zeng, S., Zeng, T., Zhan, L., Zhang, C., Zhang, F., Zhang, G., Zhang, H., Zhang, J., Zhang, K., Zhang, P., Zhang, Q., Zhang, T., Zhang, X., Zhang, Y., Zhang, Z., Zhao, J., Zhao, M., Zhao, T., Zhao, Y., Zheng, H., Zheng, M., Zheng, X., Zheng, Y., Zhong, W., Zhou, G., Zhou, J., Zhou, L., Zhou, N., Zhou, R., Zhou, S., Zhou, W., Zhou, X., Zhou, Y., Zhu, H., Zhu, K., Zhuang, H., Zong, L., and Zou, J.
- Subjects
Physics - Instrumentation and Detectors ,High Energy Physics - Experiment - Abstract
The Jiangmen Underground Neutrino Observatory (JUNO) is proposed to determine the neutrino mass hierarchy using an underground liquid scintillator detector. It is located 53 km away from both Yangjiang and Taishan Nuclear Power Plants in Guangdong, China. The experimental hall, spanning more than 50 meters, is under a granite mountain of over 700 m overburden. Within six years of running, the detection of reactor antineutrinos can resolve the neutrino mass hierarchy at a confidence level of 3-4$\sigma$, and determine neutrino oscillation parameters $\sin^2\theta_{12}$, $\Delta m^2_{21}$, and $|\Delta m^2_{ee}|$ to an accuracy of better than 1%. The JUNO detector can be also used to study terrestrial and extra-terrestrial neutrinos and new physics beyond the Standard Model. The central detector contains 20,000 tons liquid scintillator with an acrylic sphere of 35 m in diameter. $\sim$17,000 508-mm diameter PMTs with high quantum efficiency provide $\sim$75% optical coverage. The current choice of the liquid scintillator is: linear alkyl benzene (LAB) as the solvent, plus PPO as the scintillation fluor and a wavelength-shifter (Bis-MSB). The number of detected photoelectrons per MeV is larger than 1,100 and the energy resolution is expected to be 3% at 1 MeV. The calibration system is designed to deploy multiple sources to cover the entire energy range of reactor antineutrinos, and to achieve a full-volume position coverage inside the detector. The veto system is used for muon detection, muon induced background study and reduction. It consists of a Water Cherenkov detector and a Top Tracker system. The readout system, the detector control system and the offline system insure efficient and stable data acquisition and processing., Comment: 328 pages, 211 figures
- Published
- 2015
30. Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survival
- Author
-
Viet, Chi T., Dierks, Eric J., Cheng, Allen C., Patel, Ashish A., Chang, Shu-Ching, Couey, Marcus A., Watters, Amber L., Hoang, Thien, Xiao, Hong D., Crittenden, Marka R., Leidner, Rom S., Seung, Steven K., Young, Kristina H., and Bell, R. Bryan
- Published
- 2020
- Full Text
- View/download PDF
31. Ultrahigh energy storage in high-entropy ceramic capacitors with polymorphic relaxor phase
- Author
-
Zhang, Min, primary, Lan, Shun, additional, Yang, Bing B., additional, Pan, Hao, additional, Liu, Yi Q., additional, Zhang, Qing H., additional, Qi, Jun L., additional, Chen, Di, additional, Su, Hang, additional, Yi, Di, additional, Yang, Yue Y., additional, Wei, Rui, additional, Cai, Hong D., additional, Han, Hao J., additional, Gu, Lin, additional, Nan, Ce-Wen, additional, and Lin, Yuan-Hua, additional
- Published
- 2024
- Full Text
- View/download PDF
32. Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer
- Author
-
Wang Z, Zang A, Wei Y, An L, Hong D, Shi Y, Zhang J, Su S, and Fang G
- Subjects
colorectal cancer ,combination therapy ,lipid-polymer hybrid nanoparticles ,hyaluronic acid ,irinotecan ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Zhiyu Wang, Aimin Zang, Yaning Wei, Lin An, Dan Hong, Yan Shi, Jingnan Zhang, Shenyong Su, Guotao Fang Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, People’s Republic of ChinaCorrespondence: Guotao FangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, No. 648 Dongfeng East Road, Lianchi District, Baoding 071000, Hebei Province, People’s Republic of ChinaTel +86-312-5983042Email fanguotao@protonmail.comBackground: The current approach for treating colorectal cancer favors the use of drug and gene combination therapy, and targeted nano-systems are gaining considerable attention for minimizing toxicity and improving the efficacy of anticancer treatment. The aim of this study was to develop ligand-modified, irinotecan and gene co-loaded lipid-polymer hybrid nanocarriers for targeted colorectal cancer combination therapy.Methods: Hyaluronic acid modified, irinotecan and gene co-loaded LPNs (HA-I/D-LPNs) were prepared using a solvent-evaporation method. Their average size, zeta potential, drug and gene loading capacity were characterized. The in vitro and in vivo gene transfection and anti-tumor ability of this nano-system were evaluated on colorectal cancer cells and mice bearing colorectal cancer model.Results: HA-I/D-LPNs had a size of 182.3 ± 5.1, over 80% drug encapsulation efficiency and over 90% of gene loading capacity. The peak plasma concentration (Cmax) and half-life (T1/2) achieved from HA-I/D-LPNs were 41.31 ± 1.58 μg/mL and 12.56 ± 0.67 h. HA-I/D-LPNs achieved the highest tumor growth inhibition efficacy and the most prominent transfection efficiency in vivo.Conclusion: HA-I/D-LPNs exhibited the most remarkable tumor inhibition efficacy and best gene transfection efficiency in the tumor, which could prove the effects of the drug and gene combination therapy.Keywords: colorectal cancer, combination therapy, lipid-polymer hybrid nanoparticles, hyaluronic acid, irinotecan
- Published
- 2020
33. Artificial intelligence for geoscience: Progress, challenges, and perspectives
- Author
-
Zhao, T., Wang, S., Ouyang, C., Chen, M., Liu, C., Zhang, J., Yu, L., Wang, F., Xie, Y., Li, J., Grunwald, S., Wong, B.M., Zhang, F., Qian, Z., Xu, Y., Yu, C., Han, W., Sun, T., Shao, Z., Qian, T., Chen, Z., Zeng, J., Zhang, H., Letu, H., Zhang, B., Wang, L., Luo, L., Shi, C., Su, H., Yin, S., Huang, N., Zhao, W., Li, N., Zheng, C., Zhou, Y., Huang, C., Feng, D., Xu, Q., Wu, Y., Hong, D., Wang, Zhenyu, Lin, Y., Zhang, T., Kumar, P., Plaza, A., Chanussot, J., Shi, J., Zhao, T., Wang, S., Ouyang, C., Chen, M., Liu, C., Zhang, J., Yu, L., Wang, F., Xie, Y., Li, J., Grunwald, S., Wong, B.M., Zhang, F., Qian, Z., Xu, Y., Yu, C., Han, W., Sun, T., Shao, Z., Qian, T., Chen, Z., Zeng, J., Zhang, H., Letu, H., Zhang, B., Wang, L., Luo, L., Shi, C., Su, H., Yin, S., Huang, N., Zhao, W., Li, N., Zheng, C., Zhou, Y., Huang, C., Feng, D., Xu, Q., Wu, Y., Hong, D., Wang, Zhenyu, Lin, Y., Zhang, T., Kumar, P., Plaza, A., Chanussot, J., and Shi, J.
- Abstract
This paper explores the evolution of geoscientific inquiry, tracing the progression from traditional physics-based models to modern data-driven approaches facilitated by significant advancements in artificial intelligence (AI) and data collection techniques. Traditional models, which are grounded in physical and numerical frameworks, provide robust explanations by explicitly reconstructing underlying physical processes. However, their limitations in comprehensively capturing Earth’s complexities and uncertainties pose challenges in optimization and real-world applicability. In contrast, contemporary data-driven models, particularly those utilizing machine learning (ML) and deep learning (DL), leverage extensive geoscience data to glean insights without requiring exhaustive theoretical knowledge. ML techniques have shown promise in addressing Earth science-related questions. Nevertheless, challenges such as data scarcity, computational demands, data privacy concerns, and the “black-box” nature of AI models hinder their seamless integration into geoscience. The integration of physics-based and data-driven methodologies into hybrid models presents an alternative paradigm. These models, which incorporate domain knowledge to guide AI methodologies, demonstrate enhanced efficiency and performance with reduced training data requirements. This review provides a comprehensive overview of geoscientific research paradigms, emphasizing untapped opportunities at the intersection of advanced AI techniques and geoscience. It examines major methodologies, showcases advances in large-scale models, and discusses the challenges and prospects that will shape the future landscape of AI in geoscience. The paper outlines a dynamic field ripe with possibilities, poised to unlock new understandings of Earth’s complexities and further advance geoscience exploration.
- Published
- 2024
34. Spatial Gated Multi-Layer Perceptron for Land Use and Land Cover Mapping
- Author
-
Jamali, A., Kumar Roy, S., Hong, D., Atkinson, P. M., (0000-0003-1203-741X) Ghamisi, P., Jamali, A., Kumar Roy, S., Hong, D., Atkinson, P. M., and (0000-0003-1203-741X) Ghamisi, P.
- Abstract
Convolutional Neural Networks (CNNs) are models that are utilized extensively for the hierarchical extraction of features. Vision transformers (ViTs), through the use of a self-attention mechanism, have recently achieved superior modeling of global contextual information compared to CNNs. However, to realize their image classification strength, ViTs require substantial training datasets. Where the available training data are limited, current advanced multi-layer perceptrons (MLPs) can provide viable alternatives to both deep CNNs and ViTs. In this paper, we developed the SGU-MLP, a learning algorithm that effectively uses both MLPs and spatial gating units (SGUs) for precise land use land cover (LULC) mapping. Results illustrated the superiority of the developed SGU-MLP classification algorithm over several CNN and CNN-ViT-based models, including HybridSN, ResNet, iFormer, EfficientFormer and CoAtNet. The proposed SGU-MLP algorithm was tested through three experiments in Houston, USA, Berlin, Germany and Augsburg, Germany. The SGU-MLP classification model was found to consistently outperform the benchmark CNN and CNN-ViT-based algorithms. For example, for the Houston experiment, SGU-MLP significantly outperformed HybridSN, CoAtNet, Efficientformer, iFormer and ResNet by approximately 15%, 19%, 20%, 21%, and 25%, respectively, in terms of average accuracy. The code will be made publicly available at https://github.com/aj1365/SGUMLP.
- Published
- 2024
35. JUNO Conceptual Design Report
- Author
-
Adam, T, An, F, An, G, An, Q, Anfimov, N, Antonelli, V, Baccolo, G, Baldoncini, M, Baussan, E, Bellato, M, Bezrukov, L, Bick, D, Blyth, S, Boarin, S, Brigatti, A, Brugière, T, Brugnera, R, Avanzini, M Buizza, Busto, J, Cabrera, A, Cai, H, Cai, X, Cammi, A, Cao, D, Cao, G, Cao, J, Chang, J, Chang, Y, Chen, M, Chen, P, Chen, Q, Chen, S, Chen, X, Chen, Y, Cheng, Y, Chiesa, D, Chukanov, A, Clemenza, M, Clerbaux, B, D'Angelo, D, Kerret, H de, Deng, Z, Ding, X, Ding, Y, Djurcic, Z, Dmitrievsky, S, Dolgareva, M, Dornic, D, Doroshkevich, E, Dracos, M, Drapier, O, Dusini, S, Díaz, MA, Enqvist, T, Fan, D, Fang, C, Fang, J, Fang, X, Favart, L, Fedoseev, D, Fiorentini, G, Ford, R, Formozov, A, Gaigher, R, Gan, H, Garfagnini, A, Gaudiot, G, Genster, C, Giammarchi, M, Giuliani, F, Gonchar, M, Gong, G, Gong, H, Gonin, M, Gornushkin, Y, Grassi, M, Grewing, C, Gromov, V, Gu, M, Guan, M, Guarino, V, Guo, W, Guo, X, Guo, Y, Göger-Neff, M, Hackspacher, P, Hagner, C, Han, R, Han, Z, Hao, J, He, M, Hellgartner, D, Heng, Y, Hong, D, Hou, S, Hsiung, Y, and Hu, B
- Subjects
physics.ins-det ,hep-ex - Abstract
The Jiangmen Underground Neutrino Observatory (JUNO) is proposed to determinethe neutrino mass hierarchy using an underground liquid scintillator detector.It is located 53 km away from both Yangjiang and Taishan Nuclear Power Plantsin Guangdong, China. The experimental hall, spanning more than 50 meters, isunder a granite mountain of over 700 m overburden. Within six years of running,the detection of reactor antineutrinos can resolve the neutrino mass hierarchyat a confidence level of 3-4$\sigma$, and determine neutrino oscillationparameters $\sin^2\theta_{12}$, $\Delta m^2_{21}$, and $|\Delta m^2_{ee}|$ toan accuracy of better than 1%. The JUNO detector can be also used to studyterrestrial and extra-terrestrial neutrinos and new physics beyond the StandardModel. The central detector contains 20,000 tons liquid scintillator with anacrylic sphere of 35 m in diameter. $\sim$17,000 508-mm diameter PMTs with highquantum efficiency provide $\sim$75% optical coverage. The current choice ofthe liquid scintillator is: linear alkyl benzene (LAB) as the solvent, plus PPOas the scintillation fluor and a wavelength-shifter (Bis-MSB). The number ofdetected photoelectrons per MeV is larger than 1,100 and the energy resolutionis expected to be 3% at 1 MeV. The calibration system is designed to deploymultiple sources to cover the entire energy range of reactor antineutrinos, andto achieve a full-volume position coverage inside the detector. The veto systemis used for muon detection, muon induced background study and reduction. Itconsists of a Water Cherenkov detector and a Top Tracker system. The readoutsystem, the detector control system and the offline system insure efficient andstable data acquisition and processing.
- Published
- 2015
36. Correction to: A multi-site study on the impact of an advance care planning workshop on attitudes, beliefs and behavioural intentions over a 6-month period
- Author
-
Yu, C. C., Koh, E. J., Low, J. A., Ong, M. L., Sim, A. G. H., Hong, D. Y. Q., Chong, R., Low, J., and Ng, R.
- Published
- 2021
- Full Text
- View/download PDF
37. A multi-site study on the impact of an advance care planning workshop on attitudes, beliefs and behavioural intentions over a 6-month period
- Author
-
Yu, C. C., Koh, E. J., Low, J. A., Ong, M. L., Sim, A. G. H., Hong, D. Y. Q., Chong, R., Low, J., and Ng, R.
- Published
- 2021
- Full Text
- View/download PDF
38. Cutting seton for the treatment of cryptoglandular fistula-in-ano: a systematic review and meta-analysis
- Author
-
Khamar, J., primary, Sachdeva, A., additional, McKechnie, T., additional, Lee, Y., additional, Tessier, L., additional, Hong, D., additional, and Eskicioglu, C., additional
- Published
- 2023
- Full Text
- View/download PDF
39. P2.12-03 COVALENT-102: A Phase 1/1b Study of BMF-219, A Menin Inhibitor in Patients with Unresectable, Metastatic NSCLC, PDAC, and CRC
- Author
-
Patel, S., primary, Hong, D., additional, Cohen, S.A., additional, Fountzilas, C., additional, Sommerhalder, D., additional, Radhi, S., additional, Benson, A., additional, He, K., additional, Pisick, E., additional, Bessudo, A., additional, Duvivier, H., additional, Tong, T., additional, Munneke, B., additional, Kosaka, Y., additional, Ahmed, U., additional, Cacovean, A., additional, Morris, S., additional, Butler, T., additional, and Spira, A., additional
- Published
- 2023
- Full Text
- View/download PDF
40. Fractional flow reserve and fractional flow reserve gradient from coronary CT angiography for future coronary events
- Author
-
Hong, D, primary, Dai, N, additional, Lee, S H, additional, Shin, D, additional, Choi, K H, additional, Kim, S M, additional, Park, T K, additional, Yang, J H, additional, Song, Y B, additional, Hahn, J Y, additional, Choi, S H, additional, Choe, Y H, additional, Gwon, H C, additional, Ge, J, additional, and Lee, J M, additional
- Published
- 2023
- Full Text
- View/download PDF
41. Additional effects of combination therapy of antihypertensive medication on aortic elastic properties beyond blood pressure lowering effect in spontaneously hypertensive rats
- Author
-
Kim, S A, primary, Koh, A R, additional, Hong, D K, additional, and Suh, S W, additional
- Published
- 2023
- Full Text
- View/download PDF
42. Clinical outcomes of deferred lesions by IVUS versus FFR-guided treatment decision: the FLAVOUR trial substudy
- Author
-
Lee, J M, primary, Kim, H, additional, Hong, D, additional, Nam, C W, additional, Doh, J H, additional, Lee, B K, additional, Kim, W, additional, Kang, J, additional, Ahn, S G, additional, Yoon, M H, additional, Kim, U, additional, Shin, E S, additional, Koo, B K, additional, Wang, J, additional, and Hahn, J Y, additional
- Published
- 2023
- Full Text
- View/download PDF
43. Prognosis after non-infarct related artery PCI in patients with acute myocardial infarction and multivessel disease: substudy of FRAME-AMI trial
- Author
-
Hong, D, primary, Lee, S H, additional, Shin, D, additional, Kim, H K, additional, Hong, Y J, additional, Joh, H S, additional, Choi, K H, additional, Park, T K, additional, Yang, J H, additional, Song, Y B, additional, Choi, S H, additional, Jeong, M H, additional, Gwon, H C, additional, Hahn, J Y, additional, and Lee, J M, additional
- Published
- 2023
- Full Text
- View/download PDF
44. Prognostic value of cardiac magnetic resonance imaging feature tracking technology in patients with light chain amyloidosis
- Author
-
Hu, M., primary, Shen, Y., additional, Yu, H., additional, Song, Y., additional, Zheng, T., additional, Hong, D., additional, and Gong, L., additional
- Published
- 2023
- Full Text
- View/download PDF
45. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
- Author
-
Si T, Zhuo J, Feng Y, Lu H, Hong D, and Zhang LL
- Subjects
Chinese patients ,long-acting injectable ,maintenance therapy ,paliperidone palmitate once-monthly ,schizophrenia ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Tianmei Si,1,2 Jianmin Zhuo,3 Yu Feng,4 Huafei Lu,5 Di Hong,5 Lili Zhang51National Clinical Research Center for Mental Disorders & The Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, People’s Republic of China; 2Peking University Institute of Mental Health/The Sixth Hospital, Beijing, People’s Republic of China; 3Janssen (China) Research & Development Center, Johnson & Johnson (China) Investment Ltd., Shanghai, People’s Republic of China; 4Department of Neuroscience, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore; 5Medical Affairs, Xi’an Janssen Pharmaceuticals, Beijing, People’s Republic of ChinaBackground: The subgroup analysis of a primary study (NCT01051531) evaluated the effect of long-term paliperidone palmitate once-monthly (PP1M) therapy in Chinese patients with recent-onset schizophrenia responding unsatisfactorily to previous oral antipsychotics.Patients and methods: This 18-month, open-label study consisted of 3 phases – screening (7 days), treatment (18 months) and end-of-study/withdrawal visit. All enrolled patients (18–50 years) received PP1M: 150 mg eq. (day 1), 100 mg eq. (day 8) followed by a once-monthly flexible dose (50, 75, 100 or 150 mg eq.). Efficacy and safety were assessed.Results: Among the 118 enrolled Chinese patients, 68 completed the treatment (mean age: 25.6 years; male: 54.7%). A clinically meaningful change from baseline to day 548 was observed in Positive and Negative Syndrome scale (primary endpoint, mean [SD]: −15.3 [20.76]), Personal and Social Performance scale (15.9 [19.65]), Clinician Global Impression-schizophrenia score (−1.2 [1.54]) and Medication Satisfaction Questionnaire score (0.9 [1.73]). Commonly reported treatment-emergent adverse events (TEAEs) included insomnia (13.9%), injection-site pain (13.9%), upper respiratory tract infection (13.0%), restlessness (13.0%) and akathisia (13.0%). Serious TEAEs were reported in 9.3% patients with schizophrenia being most common (6.5%) and one death (suicide) was observed.Conclusion: Efficacy of PP1M corroborate findings from earlier studies and no new safety concerns emerged in this Chinese subgroup of patients with schizophrenia.Keywords: Chinese patients, long-acting injectable, maintenance therapy, paliperidone palmitate once-monthly, schizophrenia
- Published
- 2019
46. Kératoconjonctivite atopique : une allergie peut en cacher une autre. À propos d’une observation clinique avec hypersensibilité IgE médiée et hypersensibilité non IgE médiée
- Author
-
Hong, D., Coutu, A., Ferrier-Le Bouedec, M.-C., Chiambaretta, F., and Fauquert, J.-L.
- Published
- 2018
- Full Text
- View/download PDF
47. Composite Higgs from Higher Representations
- Author
-
Hong, D. K., Hsu, S. D., and Sannino, F.
- Subjects
High Energy Physics - Phenomenology ,High Energy Physics - Theory - Abstract
We investigate new models of dynamical electroweak symmetry breaking resulting from the condensation of fermions in higher representations of the technicolor group. These models lie close to the conformal window, and are free from the flavor-changing neutral current problem despite small numbers of flavors and colors. Their contribution to the S parameter is small and not excluded by precision data. The Higgs itself can be light and narrow., Comment: 4-pages, 2-columns, RevTex. Final version to appear on Physics Letters B
- Published
- 2004
- Full Text
- View/download PDF
48. The Fermion Sign Problem and High Density Effective Theory
- Author
-
Hong, D. K. and Hsu, S. D. H.
- Subjects
High Energy Physics - Phenomenology ,High Energy Physics - Lattice ,High Energy Physics - Theory ,Nuclear Theory - Abstract
We investigate the positivity of the Euclidean path integral measure for low-energy modes in dense fermionic matter. We show that the sign problem usually associated with fermions is absent if one considers only low-energy degrees of freedom. We describe a method for simulating dense QCD on the lattice and give a proof using rigorous inequalities that the color-flavor locked (CFL) phase is the true vacuum of three flavor, massless QCD., Comment: Contribution to proceedings of KIAS-APCTP Symposium on Astro-Hadron Physics, published by World Scientific. Based on talk by S. Hsu
- Published
- 2004
- Full Text
- View/download PDF
49. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
- Author
-
Naing, A, LoRusso, P, Fu, S, Hong, D, Chen, HX, Doyle, LA, Phan, AT, Habra, MA, and Kurzrock, R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Biotechnology ,Cancer ,Adrenocortical Carcinoma ,Adult ,Aged ,Antibodies ,Monoclonal ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Disease-Free Survival ,Female ,Humans ,Male ,Middle Aged ,Sirolimus ,Young Adult ,phase I clinical trials ,IGF-1R pathway ,mTOR pathway ,adrenocortical carcinoma ,cixutumumab ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundAdrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy without an available effective systemic chemotherapy. Insulin growth factor 2 (IGF-2) overexpression leading to the activation of the IGF-1 receptor (IGF-1R)/mammalian target of rapamycin (mTOR) pathway is well described in ACC. Cixutumumab, a fully human IgG1 monoclonal antibody directed at IGF-1R was combined with temsirolimus on the basis of preclinical data.MethodsPatients received cixutumumab, 3-6 mg kg(-1) intravenously (IV) weekly, and temsirolimus, 25-37.5 mg IV weekly (4-week cycles), with restaging after 8 weeks.ResultsTwenty-six patients were enrolled (13 (50%) men); median age, 47 years; median number of prior therapies, 4. Five patients previously received an IGF-1R inhibitor and one, temsirolimus. The most frequent toxicities, at least possibly drug related, were grade 1-2 thrombocytopenia (38%), mucositis (58%), hypercholesterolaemia (31%), hypertriglyceridemia (35%), and hyperglycaemia (31%). In all, 11 of 26 patients (42%) achieved stable disease (SD) >6 months (duration range=6-21 months) with 3 of the 11 having received a prior IGF-1R inhibitor.ConclusionCixutumumab combined with temsirolimus was well tolerated and >40% of patients achieved prolonged SD.
- Published
- 2013
50. FCC-hh: The Hadron Collider: Future Circular Collider Conceptual Design Report Volume 3
- Author
-
Abada, A., Abbrescia, M., AbdusSalam, S. S., Abdyukhanov, I., Abelleira Fernandez, J., Abramov, A., Aburaia, M., Acar, A. O., Adzic, P. R., Agrawal, P., Aguilar-Saavedra, J. A., Aguilera-Verdugo, J. J., Aiba, M., Aichinger, I., Aielli, G., Akay, A., Akhundov, A., Aksakal, H., Albacete, J. L., Albergo, S., Alekou, A., Aleksa, M., Aleksan, R., Alemany Fernandez, R. M., Alexahin, Y., Alía, R. G., Alioli, S., Alipour Tehrani, N., Allanach, B. C., Allport, P. P., Altınlı, M., Altmannshofer, W., Ambrosio, G., Amorim, D., Amstutz, O., Anderlini, L., Andreazza, A., Andreini, M., Andriatis, A., Andris, C., Andronic, A., Angelucci, M., Antinori, F., Antipov, S. A., Antonelli, M., Antonello, M., Antonioli, P., Antusch, S., Anulli, F., Apolinário, L., Apollinari, G., Apollonio, A., Appelö, D., Appleby, R. B., Apyan, A., Apyan, A., Arbey, A., Arbuzov, A., Arduini, G., Arı, V., Arias, S., Armesto, N., Arnaldi, R., Arsenyev, S. A., Arzeo, M., Asai, S., Aslanides, E., Aßmann, R. W., Astapovych, D., Atanasov, M., Atieh, S., Attié, D., Auchmann, B., Audurier, A., Aull, S., Aumon, S., Aune, S., Avino, F., Avrillaud, G., Aydın, G., Azatov, A., Azuelos, G., Azzi, P., Azzolini, O., Azzurri, P., Bacchetta, N., Bacchiocchi, E., Bachacou, H., Baek, Y. W., Baglin, V., Bai, Y., Baird, S., Baker, M. J., Baldwin, M. J., Ball, A. H., Ballarino, A., Banerjee, S., Barber, D. P., Barducci, D., Barjhoux, P., Barna, D., Barnaföldi, G. G., Barnes, M. J., Barr, A., Barranco García, J., Barreiro Guimarães da Costa, J., Bartmann, W., Baryshevsky, V., Barzi, E., Bass, S. A., Bastianin, A., Baudouy, B., Bauer, F., Bauer, M., Baumgartner, T., Bautista-Guzmán, I., Bayındır, C., Beaudette, F., Bedeschi, F., Béguin, M., Bellafont, I., Bellagamba, L., Bellegarde, N., Belli, E., Bellingeri, E., Bellini, F., Bellomo, G., Belomestnykh, S., Bencivenni, G., Benedikt, M., Bernardi, G., Bernardi, J., Bernet, C., Bernhardt, J. M., Bernini, C., Berriaud, C., Bertarelli, A., Bertolucci, S., Besana, M. I., Besançon, M., Beznosov, O., Bhat, P., Bhat, C., Biagini, M. E., Biarrotte, J. -L., Bibet Chevalier, A., Bielert, E. R., Biglietti, M., Bilei, G. M., Bilki, B., Biscari, C., Bishara, F., Blanco-García, O. R., Blánquez, F. R., Blekman, F., Blondel, A., Blümlein, J., Boccali, T., Boels, R., Bogacz, S. A., Bogomyagkov, A., Boine-Frankenheim, O., Boland, M. J., Bologna, S., Bolukbasi, O., Bomben, M., Bondarenko, S., Bonvini, M., Boos, E., Bordini, B., Bordry, F., Borghello, G., Borgonovi, L., Borowka, S., Bortoletto, D., Boscherini, D., Boscolo, M., Boselli, S., Bosley, R. R., Bossu, F., Botta, C., Bottura, L., Boughezal, R., Boutin, D., Bovone, G., Božović Jelisavić, I., Bozbey, A., Bozzi, C., Bozzini, D., Braccini, V., Braibant-Giacomelli, S., Bramante, J., Braun-Munzinger, P., Briffa, J. A., Britzger, D., Brodsky, S. J., Brooke, J. J., Bruce, R., De Renstrom, P. Brückman, Bruna, E., Brüning, O., Brunner, O., Brunner, K., Bruzzone, P., Buffat, X., Bulyak, E., Burkart, F., Burkhardt, H., Burnet, J. -P., Butin, F., Buttazzo, D., Butterworth, A., Caccia, M., Cai, Y., Caiffi, B., Cairo, V., Cakir, O., Calaga, R., Calatroni, S., Calderini, G., Calderola, G., Caliskan, A., Calvet, D., Calviani, M., Camalich, J. M., Camarri, P., Campanelli, M., Camporesi, T., Canbay, A. C., Canepa, A., Cantergiani, E., Cantore-Cavalli, D., Capeans, M., Cardarelli, R., Cardella, U., Cardini, A., Carloni Calame, C. M., Carra, F., Carra, S., Carvalho, A., Casalbuoni, S., Casas, J., Cascella, M., Castelnovo, P., Castorina, G., Catalano, G., Cavasinni, V., Cazzato, E., Cennini, E., Cerri, A., Cerutti, F., Cervantes, J., Chaikovska, I., Chakrabortty, J., Chala, M., Chamizo-Llatas, M., Chanal, H., Chanal, D., Chance, S., Chancé, A., Charitos, P., Charles, J., Charles, T. K., Chattopadhyay, S., Chehab, R., Chekanov, S. V., Chen, N., Chernoded, A., Chetvertkova, V., Chevalier, L., Chiarelli, G., Chiarello, G., Chiesa, M., Chiggiato, P., Childers, J. T., Chmielińska, A., Cholakian, A., Chomaz, P., Chorowski, M., Chou, W., Chrzaszcz, M., Chyhyrynets, E., Cibinetto, G., Ciftci, A. K., Ciftci, R., Cimino, R., Ciuchini, M., Clark, P. J., Coadou, Y., Cobal, M., Coccaro, A., Cogan, J., Cogneras, E., Collamati, F., Colldelram, C., Collier, P., Collot, J., Contino, R., Conventi, F., Cook, C. T. A., Cooley, L., Corcella, G., Cornell, A. S., Corral, G. H., Correia-Rodrigues, H., Costanza, F., Costa Pinto, P., Couderc, F., Coupard, J., Craig, N., Crespo Garrido, I., Crivellin, A., Croteau, J. F., Crouch, M., Cruz Alaniz, E., Curé, B., Curti, J., Curtin, D., Czech, M., Dachauer, C., D’Agnolo, R. T., Daibo, M., Dainese, A., Dalena, B., Daljevec, A., Dallapiazza, W., D’Aloia Schwartzentruber, L., Dam, M., D’Ambrosio, G., Das, S. P., DasBakshi, S., da Silva, W., da Silveira, G. G., D’Auria, V., D’Auria, S., David, A., Davidek, T., Deandrea, A., de Blas, J., Debono, C. J., De Curtis, S., De Filippis, N., de Florian, D., Deghaye, S., de Jong, S. J., Del Bo, C., Del Duca, V., Delikaris, D., Deliot, F., Dell’Acqua, A., Delle Rose, L., Delmastro, M., De Lucia, E., Demarteau, M., Denegri, D., Deniau, L., Denisov, D., Denizli, H., Denner, A., d’Enterria, D., de Rijk, G., De Roeck, A., Derue, F., Deschamps, O., Descotes-Genon, S., Dev, P. S. B., de Vivie de Régie, J. B., Dewanjee, R. K., Di Ciaccio, A., Di Cicco, A., Dillon, B. M., Di Micco, B., Di Nezza, P., Di Vita, S., Doblhammer, A., Dominjon, A., D’Onofrio, M., Dordei, F., Drago, A., Draper, P., Drasal, Z., Drewes, M., Duarte, L., Dubovyk, I., Duda, P., Dudarev, A., Dudko, L., Duellmann, D., Dünser, M., du Pree, T., Durante, M., Duran Yildiz, H., Dutta, S., Duval, F., Duval, J. M., Dydyshka, Y., Dziewit, B., Eisenhardt, S., Eisterer, M., Ekelof, T., El Khechen, D., Ellis, S. A., Ellis, J., Ellison, J. A., Elsener, K., Elsing, M., Enari, Y., Englert, C., Eriksson, H., Eskola, K. J., Esposito, L. S., Etisken, O., Etzion, E., Fabbricatore, P., Falkowski, A., Falou, A., Faltova, J., Fan, J., Fanò, L., Farilla, A., Farinelli, R., Farinon, S., Faroughy, D. A., Fartoukh, S. D., Faus-Golfe, A., Fawcett, W. J., Felici, G., Felsberger, L., Ferdeghini, C., Fernandez Navarro, A. M., Fernández-Téllez, A., Ferradas Troitino, J., Ferrara, G., Ferrari, R., Ferreira, L., Ferreira da Silva, P., Ferrera, G., Ferro, F., Fiascaris, M., Fiorendi, S., Fiorio, C., Fischer, O., Fischer, E., Flieger, W., Florio, M., Fonnesu, D., Fontanesi, E., Foppiani, N., Foraz, K., Forkel-Wirth, D., Forte, S., Fouaidy, M., Fournier, D., Fowler, T., Fox, J., Francavilla, P., Franceschini, R., Franchino, S., Franco, E., Freitas, A., Fuks, B., Furukawa, K., Furuseth, S. V., Gabrielli, E., Gaddi, A., Galanti, M., Gallo, E., Ganjour, S., Gao, J., Gao, J., Garcia Diaz, V., García Pérez, M., García Tabarés, L., Garion, C., Garzelli, M. V., Garzia, I., Gascon-Shotkin, S. M., Gaudio, G., Gay, P., Ge, S. -F., Gehrmann, T., Genest, M. H., Gerard, R., Gerigk, F., Gerwig, H., Giacomelli, P., Giagu, S., Gianfelice-Wendt, E., Gianotti, F., Giffoni, F., Gilardoni, S. S., Gil Costa, M., Giovannetti, M., Giovannozzi, M., Giubellino, P., Giudice, G. F., Giunta, A., Gladilin, L. K., Glukhov, S., Gluza, J., Gobbi, G., Goddard, B., Goertz, F., Golling, T., Goncalves, V. P., Gonçalo, R., Gonzalez Gomez, L. A., Gorgi Zadeh, S., Gorine, G., Gorini, E., Gourlay, S. A., Gouskos, L., Grancagnolo, F., Grassellino, A., Grau, A., Graverini, E., Gray, H. M., Greco, Ma., Greco, Mi., Grenard, J. -L., Grimm, O., Grojean, C., Gromov, V. A., Grosse-Oetringhaus, J. F., Grudiev, A., Grzanka, K., Gu, J., Guadagnoli, D., Guidi, V., Guiducci, S., Guillermo Canton, G., Günaydin, Y. O., Gupta, R., Gupta, R. S., Gutierrez, J., Gutleber, J., Guyot, C., Guzey, V., Gwenlan, C., Haberstroh, C., Hacışahinoğlu, B., Haerer, B., Hahn, K., Hahn, T., Hammad, A., Han, C., Hance, M., Hannah, A., Harris, P. C., Hati, C., Haug, S., Hauptman, J., Haurylavets, V., He, H. -J., Hegglin, A., Hegner, B., Heinemann, K., Heinemeyer, S., Helsens, C., Henriques, A., Henriques, A., Hernandez, P., Hernández-Pinto, R. J., Hernandez-Sanchez, J., Herzig, T., Hiekkanen, I., Hillert, W., Hoehn, T., Hofer, M., Höfle, W., Holdener, F., Holleis, S., Holzer, B., Hong, D. K., Honorato, C. G., Hopkins, S. C., Hrdinka, J., Hug, F., Humann, B., Humer, H., Hurth, T., Hutton, A., Iacobucci, G., Ibarrola, N., Iconomidou-Fayard, L., Ilyina-Brunner, K., Incandela, J., Infantino, A., Ippolito, V., Ishino, M., Islam, R., Ita, H., Ivanovs, A., Iwamoto, S., Iyer, A., Izquierdo Bermudez, S., Jadach, S., Jamin, D. O., Janot, P., Jarry, P., Jeff, A., Jenny, P., Jensen, E., Jensen, M., Jiang, X., Jiménez, J. M., Jones, M. A., Jones, O. R., Jowett, J. M., Jung, S., Kaabi, W., Kado, M., Kahle, K., Kalinovskaya, L., Kalinowski, J., Kamenik, J. F., Kannike, K., Kara, S. O., Karadeniz, H., Karaventzas, V., Karpov, I., Kartal, S., Karyukhin, A., Kashikhin, V., Katharina Behr, J., Kaya, U., Keintzel, J., Keinz, P. A., Keppel, K., Kersevan, R., Kershaw, K., Khanpour, H., Khatibi, S., Khatiri Yanehsari, M., Khoze, V. V., Kieseler, J., Kilic, A., Kilpinen, A., Kim, Y. -K., Kim, D. W., Klein, U., Klein, M., Kling, F., Klinkenberg, N., Klöppel, S., Klute, M., Klyukhin, V. I., Knecht, M., Kniehl, B., Kocak, F., Koeberl, C., Kolano, A. M., Kollegger, A., Kołodziej, K., Kolomiets, A. A., Komppula, J., Koop, I., Koppenburg, P., Koratzinos, M., Kordiaczyńska, M., Korjik, M., Kortner, O., Kostka, P., Kotlarski, W., Kotnig, C., Köttig, T., Kotwal, A. V., Kovalenko, A. D., Kowalski, S., Kozaczuk, J., Kozlov, G. A., Kozub, S. S., Krainer, A. M., Kramer, T., Krämer, M., Krammer, M., Krasnov, A. A., Krauss, F., Kravalis, K., Kretzschmar, L., Kriske, R. M., Kritscher, H., Krkotic, P., Kroha, H., Kucharczyk, M., Kuday, S., Kuendig, A., Kuhlmann, G., Kulesza, A., Kumar, M., Kumar, M., Kusina, A., Kuttimalai, S., Kuze, M., Kwon, T., Lackner, F., Lackner, M., La Francesca, E., Laine, M., Lamanna, G., La Mendola, S., Lançon, E., Landsberg, G., Langacker, P., Lange, C., Langner, A., Lankford, A. J., Lansberg, J. P., Lari, T., Laycock, P. J., Lebrun, P., Lechner, A., Lee, K., Lee, S., Lee, R., Lefevre, T., Le Guen, P., Lehtinen, T., Leith, S. B., Lenzi, P., Leogrande, E., Leonidopoulos, C., Leon-Monzon, I., Lerner, G., Leroy, O., Lesiak, T., Lévai, P., Leveratto, A., Levichev, E., Li, G., Li, S., Li, R., Liberati, D., Liepe, M., Lissauer, D. A., Liu, Z., Lobko, A., Locci, E., Logothetis Agaliotis, E., Lombardo, M. P., Long, A. J., Lorin, C., Losito, R., Louzguiti, A., Low, I., Lucchesi, D., Lucchini, M. T., Luciani, A., Lueckhof, M., Lunt, A. J. G., Luzum, M., Lyubimtsev, D. A., Maggiora, M., Magnin, N., Mahmoud, M. A., Mahmoudi, F., Maitre, J., Makarenko, V., Malagoli, A., Malclés, J., Malgeri, L., Mallon, P. J., Maltoni, F., Malvezzi, S., Malyshev, O. B., Mancinelli, G., Mandrik, P., Manfrinetti, P., Mangano, M., Manil, P., Mannelli, M., Marchiori, G., Marhauser, F., Mariani, V., Marinozzi, V., Mariotto, S., Marquard, P., Marquet, C., Marriott-Dodington, T., Martin, R., Martin, O., Martin Camalich, J., Martinez, T., Martinez Bruzual, H., Martínez-Hernández, M. I., Martins, D. E., Marzani, S., Marzocca, D., Marzola, L., Masciocchi, S., Masina, I., Massimiliano, A., Massironi, A., Masubuchi, T., Matveev, V. A., Mazzoni, M. A., McCullough, M., McIntosh, P. A., Meade, P., Medina, L., Meier, A., Meignan, J., Mele, B., Mendes Saraiva, J. G., Menez, F., Mentink, M., Meoni, E., Meridiani, P., Merk, M., Mermod, P., Mertens, V., Mether, L., Métral, E., Migliorati, M., Milanese, A., Milardi, C., Milhano, G., Militsyn, B. L., Millet, F., Minashvili, I., Minervini, J. V., Miralles, L. S., Mirarchi, D., Mishima, S., Missiaen, D. P., Mitselmakher, G., Mitshuhashi, T., Mnich, J., Mohammadi Najafabadi, M., Mohapatra, R. N., Mokhov, N., Molson, J. G., Monge, R., Montag, C., Montagna, G., Monteil, S., Montenero, G., Montesinos, E., Moortgat, F., Morange, N., Morello, G., Moreno Llácer, M., Moretti, M., Moretti, S., Morley, A. K., Moros, A., Morozov, I., Morretta, V., Morrone, M., Mostacci, A., Muanza, S., Muchnoi, N., Mühlegger, M., Mulder, M., Mulders, M., Müller, B., Müller, F., Müller, A. -S., Munilla, J., Murray, M. J., Muttoni, Y., Myers, S., Mylona, M., Nachtman, J., Nakamoto, T., Nardecchia, M., Nardini, G., Nason, P., Nergiz, Z., Nesterenko, A. V., Netto, J. A., Nettsträter, A., Neubüser, C., Neundorf, J., Niccoli, F., Nicrosini, O., Nie, Y., Niedermayer, U., Niedziela, J., Niemi, A., Nikitin, S. A., Nisati, A., No, J. M., Nonis, M., Nosochkov, Y., Novák, M., Novokhatski, A., O’Callaghan, J. M., Ochando, C., Ogur, S., Ohmi, K., Oide, K., Okorokov, V. A., Okumura, Y., Oleari, C., Olness, F. I., Onel, Y., Ortino, M., Osborne, J., Osland, P., Otto, T., Oyulmaz, K. Y., Ozansoy, A., Özcan, V., Özdemir, K., Pagliarone, C. E., Pais da Silva, H. F., Palmieri, E., Palumbo, L., Pampaloni, A., Pan, R. -Q., Panareo, M., Panella, O., Panico, G., Panizzo, G., Pankov, A. A., Pantsyrny, V., Papadopoulos, C. G., Papaefstathiou, A., Papaphilippou, Y., Parker, M. A., Parma, V., Pasquali, M., Patra, S. K., Patterson, R., Paukkunen, H., Pauss, F., Peggs, S., Penttinen, J. -P., Peón, G., Perepelkin, E. E., Perez, E., Perez, J. C., Perez, G., Pérez, F., Perez Codina, E., Perez Morales, J., Perfilov, M., Pernegger, H., Peruzzi, M., Pes, C., Peters, K., Petracca, S., Petriello, F., Pezzotti, L., Pfeiffer, S., Piccinini, F., Pieloni, T., Pierini, M., Pikhartova, H., Pikurs, G., Pilicer, E., Piminov, P., Pira, C., Pittau, R., Płaczek, W., Plagge, M., Plehn, T., Pleier, M. -A., Płoskoń, M., Podeur, M., Podlech, H., Podzorny, T., Poggioli, L., Poiron, A., Polesello, G., Poli Lener, M., Polini, A., Polinski, J., Polozov, S. M., Ponce, L., Pont, M., Pontecorvo, L., Portaluri, T., Potamianos, K., Prasse, C., Prausa, M., Preinerstorfer, A., Premat, E., Price, T., Primavera, M., Prino, F., Prioli, M., Proudfoot, J., Provino, A., Pugnat, T., Pukhaeva, N., Puławski, S., Pulikowski, D., Punzi, G., Putti, M., Pyarelal, A., Quack, H., Quispe, M., Racioppi, A., Rafique, H., Raginel, V., Raidal, M., Ramírez-Uribe, N. S., Ramsey-Musolf, M. J., Rata, R., Ratoff, P., Ravotti, F., Rebello Teles, P., Reboud, M., Redaelli, S., Renner, E., Rentería-Olivo, A. E., Rescigno, M., Reuter, J., Ribon, A., Ricci, A. M., Riegler, W., Riemann, S., Riemann, B., Riemann, T., Rifflet, J. M., Rimmer, R. A., Rinaldesi, R., Rinolfi, L., Rios Rubiras, O., Risselada, T., Rivetti, A., Rivkin, L., Rizzo, T., Robens, T., Robert, F., Robson, A. J., Rochepault, E., Roda, C., Rodrigo, G., Rodríguez-Cahuantzi, M., Rogan, C., Roig, M., Rojas-Torres, S., Rojo, J., Rolandi, G., Rolando, G., Roloff, P., Romanenko, A., Romanov, A., Roncarolo, F., Rosado Sanchez, A., Rosaz, G., Rossi, L., Rossi, A., Rossmanith, R., Rousset, B., Royon, C., Ruan, X., Ruehl, I., Ruhlmann-Kleider, V., Ruiz, R., Rumyantsev, L., Ruprecht, R., Ryazanov, A. I., Saba, A., Sadykov, R., Saez de Jauregui, D., Sahin, M., Sailer, B., Saito, M., Sala, F., Salam, G. P., Salfeld-Nebgen, J., Salgado, C. A., Salini, S., Sallese, J. M., Salmi, T., Salzburger, A., Sampayo, O. A., Sanfilippo, S., Santiago, J., Santopinto, E., Santoro, R., Sanz Ull, A., Sarasola, X., Sarpün, I. H., Sauvain, M., Savelyeva, S., Sawada, R., Sborlini, G. F. R., Schaffer, A., Schaumann, M., Schenk, M., Scheuerlein, C., Schienbein, I., Schlenga, K., Schmickler, H., Schmidt, R., Schoerling, D., Schoning, A., Schörner-Sadenius, T., Schott, M., Schulte, D., Schwaller, P., Schwanenberger, C., Schwemling, P., Schwerg, N., Scibile, L., Sciuto, A., Scomparin, E., Sebastiani, C., Seeber, B., Segreti, M., Selva, P., Selvaggi, M., Senatore, C., Senol, A., Serin, L., Serluca, M., Serra, N., Seryi, A., Sestini, L., Sfyrla, A., Shaposhnikov, M., Shaposhnikova, E., Sharkov, B. Y., Shatilov, D., Shelton, J., Shiltsev, V., Shipsey, I. P., Shirkov, G. D., Shivaji, A., Shwartz, D., Sian, T., Sidorov, S., Siemko, A., Silvestrini, L., Simand, N., Simon, F., Singh, B. K., Siódmok, A., Sirois, Y., Sirtori, E., Sirvinskaite, R., Sitar, B., Sjöstrand, T., Skands, P., Skordis, E., Skovpen, K., Skrzypek, M., Slade, E., Slavich, P., Slovak, R., Smaluk, V., Smirnov, V., Snoeys, W., Soffi, L., Sollander, P., Solovyanov, O., Soltveit, H. K., Song, H., Sopicki, P., Sorbi, M., Spallino, L., Spannowsky, M., Spataro, B., Sphicas, P., Spiesberger, H., Spiller, P., Spira, M., Srivastava, T., Stachel, J., Stakia, A., Stanyard, J. L., Starchenko, E., Starikov, A. Y., Staśto, A. M., Statera, M., Steerenberg, R., Steggemann, J., Stenvall, A., Stivanello, F., Stöckinger, D., Stoel, L. S., Stöger-Pollach, M., Strauss, B., Stuart, M., Stupakov, G., Su, S., Sublet, A., Sugita, K., Sulak, L., Sullivan, M. K., Sultansoy, S., Sumida, T., Suzuki, K., Sylva, G., Syphers, M. J., Sznajder, A., Taborelli, M., Tahir, N. A., Takeuchi, M., Tal Hod, E., Tambasco, C., Tanaka, J., Tang, K., Tapan, I., Taroni, S., Tartarelli, G. F., Tassielli, G., Tavian, L., Taylor, T. M., Taylor, G. N., Teixeira, A. M., Tejeda-Muñoz, G., Telnov, V. I., Tenchini, R., ten Kate, H. H. J., Terashi, K., Tesi, A., Testa, M., Tetrel, C., Teytelman, D., Thaler, J., Thamm, A., Thomas, S., Tiirakari, M. T., Tikhomirov, V., Tikhonov, D., Timko, H., Tisserand, V., Tkachenko, L. M., Tkaczuk, J., Tock, J. P., Todd, B., Todesco, E., Tomás Garcia, R., Tommasini, D., Tonelli, G., Toral, F., Torims, T., Torre, R., Townsend, Z., Trant, R., Treille, D., Trentadue, L., Tricoli, A., Tricomi, A., Trischuk, W., Tropin, I. S., Tuchming, B., Tudora, A. A., Turbiarz, B., Turk Cakir, I., Turri, M., Tydecks, T., Usovitsch, J., Uythoven, J., Vaglio, R., Valassi, A., Valchkova, F., Valdivia Garcia, M. A., Valente, P., Valente, R. U., Valente-Feliciano, A. -M., Valentino, G., Vale Silva, L., Valet, J. M., Valizadeh, R., Valle, J. W. F., Vallecorsa, S., Vallone, G., van Leeuwen, M., van Rienen, U. H., van Riesen-Haupt, L., Varasteh, M., Vecchi, L., Vedrine, P., Velev, G., Veness, R., Ventura, A., Venturini Delsolaro, W., Verducci, M., Verhaaren, C. B., Vernieri, C., Verweij, A. P., Verwilligen, O., Viazlo, O., Vicini, A., Viehhauser, G., Vignaroli, N., Vignolo, M., Vitrano, A., Vivarelli, I., Vlachos, S., Vogel, M., Vogt, D. M., Völkl, V., Volkov, P., Volpini, G., von Ahnen, J., Vorotnikov, G., Voutsinas, G. G., Vysotsky, V., Wagner, U., Wallny, R., Wang, L. -T., Wang, R., Wang, K., Ward, B. F. L., Watson, T. P., Watson, N. K., Ws, Z., Weiland, C., Weinzierl, S., Welsch, C. P., Wenninger, J., Widorski, M., Wiedemann, U. A., Wienands, H. -U., Wilkinson, G., Williams, P. H., Winter, A., Wohlfahrt, A., Wojtoń, T., Wollmann, D., Womersley, J., Woog, D., Wu, X., Wulzer, A., Yanehsari, M. K., Yang, G., Yang, H. J., Yao, W. -M., Yazgan, E., Yermolchik, V., Yilmaz, A., Yilmaz, A., Yoo, H. -D., Yost, S. A., You, T., Young, C., Yu, T. -T., Yu, F., Zaborowska, A., Zadeh, S. G., Zahnd, M., Zanetti, M., Zanotto, L., Zawiejski, L., Zeiler, P., Zerlauth, M., Zernov, S. M., Zevi Dell Porta, G., Zhang, Z., Zhang, Y., Zhang, C., Zhang, H., Zhao, Z., Zhong, Y. -M., Zhou, J., Zhou, D., Zhuang, P., Zick, G., Zimmermann, F., Zinn-Justin, J., Zivkovic, L., Zlobin, A. V., Zobov, M., Zupan, J., Zurita, J., and the FCC Collaboration
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.